HealthCare Middle East & Africa - Issue 10

FOUNDER & PUBLISHER

Francis Juma

SENIOR EDITOR

Paul Ongeto EDITORS

Vincent Moranga | Steve Ireri | Jackie Muinde

BUSINESS DEVELOPMENT DIRECTOR

Virginia Nyoro

BUSINESS DEVELOPMENT ASSOCIATE

Elly Okutoyi

HEAD OF DESIGN

Clare Ngode

DESIGN

Yvonne Njambi

CINEMATOGRAPHER

Newton Lemein

ACCOUNTS

Jonah Sambai

Healthcare funding gap in

Africa

poses a greater risk than governments want to imagine

Welcome to our 10th issue of Healthcare Middle East & Africa Magazine

The Kenyan healthcare system is in crisis, as evidenced by the ongoing doctors’ strike. They are demanding comprehensive medical coverage and the hiring of 1,200 medical interns. The Health Acting DirectorGeneral, Patrick Amoth, acknowledges the challenges but cites a lack of funds to address the medics’ demands.

This scenario is unfortunately replicated across Africa, where doctors are forced to strike repeatedly to pressure governments for increased healthcare spending. The response from governments is predictable: a lack of funds. This is despite a pledge made 24 years ago by African nations to allocate 15% of their annual budgets to healthcare. Only a small fraction have met this target.

The chronic underfunding of healthcare has led to a system overwhelmed and stretched beyond capacity. Hospitals have

become dilapidated facilities lacking basic infrastructure for even essential surgeries. Pharmacies are frequently bare, forcing patients to source personal protective equipment (PPE) like gloves. Staffing shortages are severe, with the average doctor-to-patient ratio in Africa estimated at a meager 0.2 per 1,000 – far short of the WHO’s recommended 2.5 per 1,000.

These factors create a vicious cycle of strikes and minimal progress. Losing hope, many doctors leave the continent seeking better opportunities in wealthier nations.

This issue explores how this exodus harms healthcare delivery across Africa and how Mercy Ships, with its innovative hospital ships, bridges the gap. Their innovative hospital ships, equipped with cutting-edge technology and staffed by volunteer medical professionals, bring critical surgical services to vulnerable communities across Africa. Mercy Ships exemplifies the transformative potential of channelling resources towards healthcare.

We also gain exclusive insights from the Kenya Medical Association President and CEO on their advocacy efforts for doctor welfare and ensuring quality healthcare access for Kenyans.

Beyond this spotlight, we explore progress in HIV management and the burgeoning influence of artificial intelligence on healthcare delivery.

This issue is packed with insightful articles, keeping you abreast of the latest news and innovations shaping Africa’s healthcare landscape, and beyond.

We hope that you enjoy your read.

Paul Ongeto Senior Editor, FW Africa

MILLING

KENYA

TOPICAL FOCUS: BRAIN DRAIN

Healing the Rift: Addressing Brain Drain In Africa’s Healthcare Sector

HEALTHCARE TRENDS: AI IN HEALTHCARE

COUNTRY FOCUS: QATAR 46 Qatar : Middle East and Africa’s leader in healthcare delivery Transforming Patient Care, One Innovation at a Time

World Bank pledges

US$120M for vaccine plant in Kenya

KENYA - The World Bank has pledged US$120 million to support Kenya’s vaccine manufacturing plant, set to start operations in 2029.

Health Principal Secretary Harry Kimutai disclosed this during a visit with World Bank Vice President Mamta Murthi to the facility in Embakasi, Nairobi.

The Kenya BioVax Institute is constructing the plant, equipped with two filling lines to meet Kenya’s growing annual vaccination demand, projected to reach 25 million doses due to population growth.

The World Bank’s funding highlights its crucial role in Kenya’s development efforts, including health infrastructure and energy projects.

Murthi commended Kenya’s progress in vaccine production, stressing the facility’s significance in maintaining regional vaccine supply, particularly amid Gavi’s expected departure, Kenya’s principal vaccine donor.

Gavi has extended support until 2029 to bolster the Kenya Biovax Institute’s capacity for local vaccine production.

Meanwhile, the Institute has also signed a Memorandum of Understanding with Hayat Biotech of the UAE, witnessed by President Ruto.

The agreement aims to strengthen scientific research capacity in vaccine manufacturing and research within Kenya and the East African Community (EAC), aligning with Kenya’s goal of self-sufficiency in vaccine production.

Hayat Biotech’s advanced biotechnology facilities and commitment to medical science position it as a reliable partner for vaccine research, development, and manufacturing, enhancing Kenya’s capability in this critical sector.

Novo Nordisk strikes deal to acquire Cardior Pharmaceuticals for US$1.11B

DENMARK — Novo Nordisk has agreed to acquire Cardior Pharmaceuticals, a leading clinical-stage biopharmaceutical company, for up to €1.03 billion (US$1.11b).

This move aligns with Novo’s strategic objective to expand its focus beyond diabetes and weight-loss therapies to include treatments for cardiovascular diseases.

The acquisition encompasses Cardior’s lead compound CDR132L, currently undergoing intermediate Phase II clinical trials for heart failure treatment, according to Novo.

This compound is designed to arrest and partially reverse the progression of heart failure, potentially leading to sustained improvement in heart function.

Novo Nordisk intends to initiate a second Phase II trial investigating CDR132L in individuals with cardiac hypertrophy, a condition characterized by thickened and stiffened heart muscle walls, impairing the heart’s ability to pump blood effectively.

Expected to be finalized in the second quarter of this year, the deal is projected not to affect Novo’s operating profit guidance for 2024.

Cleopatra Hospitals commits US$41M to expand operations over next 18 months

EGYPT—The Cleopatra Hospitals Group (CHG) has announced that it intends to invest EGP 2 billion (US$41 million) to expand in the Egyptian healthcare market in the next 18 months.

The hospital chain announced that it would direct the dedicated investments to the construction of the first and second phases of the Sky Hospital project in East Cairo, the expansion of the Cleopatra October facilities in West Cairo and expanding polyclinic activities across Greater Cairo.

According to CHG managing director Ahmed Ezz, the 40-bed first phase will also include a radiology center, an emergency department, operating rooms, and a pharmacy.

CHG said that it plans to add more than 300 beds to its healthcare facilities in Greater Cairo and generate over 750 new jobs.

Polyclinics are healthcare facilities

that provide general and specialist examinations and treatments for a wide variety of diseases and injuries to outpatients and are usually independent of a hospital.

The expansion aligns with projections outlined in a report by the African Development Bank, which estimates Egypt’s need for approximately 38,000 new hospital beds by 2030, requiring significant investments, with the public sector expected to fund a substantial portion.

Moreover, Egypt’s commitment to bolstering healthcare is evident, with the government announcing plans to increase healthcare spending by 15 percent in the fiscal year 2023/2024, as disclosed by Mohamed Maait, the Minister of Finance and head of the General Authority for the Universal Health Insurance System.

Africa CDC donates Cold Chain Equipment to five nations

AFRICA - The Africa Centres for Disease Control and Prevention (Africa CDC), in collaboration with the Mastercard Foundation, has donated state-of-theart cold chain equipment to five African Union Member States under the Saving Lives and Livelihoods program.

The initiative aims to bolster healthcare systems and enhance responses to vaccine-preventable diseases. Initial recipients include Botswana, Cameroon, Sierra Leone, Uganda, and Zambia, with plans to benefit a total of 32 countries.

Valued at up to US$3.3 million, the equipment encompasses refrigerators, freezers, temperature monitors, vaccine carriers, cold boxes, and cold rooms, procured and distributed with UNICEF’s support.

This technology is crucial for efficiently handling vaccines and critical medical supplies, thereby expanding COVID-19 vaccination efforts and routine vaccination programs to reach all children.

By increasing cold chain storage capacity, ministries of health can enhance vaccination coverage rates and offer more comprehensive vaccination programs.

Meanwhile, in Kenya, the Ministry of Health has allocated cold chain equipment worth KES1 billion (US$7.017 million) to all 47 counties to improve cold chain equipment availability.

This initiative follows a 2016 statewide assessment that revealed gaps in cold chain equipment availability, leading to collaboration between the

Ministry of Health and Gavi to provide 1,483 units of cold chain equipment to all counties by 2017.

THE INITIATIVE AIMS TO BOLSTER HEALTHCARE SYSTEMS AND ENHANCE RESPONSES TO VACCINEPREVENTABLE DISEASES.

AstraZeneca completes Icosavax acquisition for US$1.1B

USA— British pharmaceutical giant AstraZenec has finalized the acquisition of Icosavax, a clinical-stage biopharmaceutical company, in a deal valued at US$1.1 billion.

Initially announced in December 2023, the acquisition involved a tender offer for all outstanding shares of Icosavax at US$15 each, complemented by additional contingent value rights.

AstraZeneca aims to leverage Icosavax's innovative protein viruslike particle (VLP) platform to develop

a robust portfolio of vaccines with enhanced efficacy and safety profiles.

With the completion of the acquisition, Icosavax will now operate as a subsidiary of AstraZeneca, with headquarter in Seattle, United States.

In addition to the Icosavax acquisition, AstraZeneca has been actively expanding its rare disease division, with recent acquisitions including Amolyt Pharma, an endocrine disease specialist funded by Novo Holdings.

This move follows AstraZeneca's

acquisition of Alexion three years ago for US$39 billion, propelling the company into the forefront of rare disease treatment.

The acquisition of Amolyt Pharma further underscores AstraZeneca's commitment to rare disease research and development.

The deal involves an upfront payment of US$800 million to Amolyt stockholders, with an additional US$250 million contingent upon meeting specified regulatory milestones.

With this acquisition, AstraZeneca gains access to eneboparatide, a Phase 3 drug aimed at treating hypoparathyroidism, a condition affecting approximately 115,000 people in the United States.

Additionally, Amolyt's pipeline includes AZP-3813, an experimental medicine targeting acromegaly, a disorder characterized by excessive growth hormone production.

MANUFACTURING

Africa vows to produce 60% of its vaccines by 2040

AFRICA - The African Union, through the African Center for Disease Control and Prevention (Africa CDC), has set a goal to address 60% of the continent’s vaccine needs by 2040.

This commitment was announced

HEALTHCARE DELIVERY

during a high-level breakfast meeting with the International Vaccine Institute and Africa CDC, held on the margins of the 37th Ordinary Session of the African Union in Addis Ababa, Ethiopia.

President William Ruto of Kenya underscored the critical importance of African countries producing their vaccines to combat disease pandemics effectively.

He pointed out the challenges Africa faced during the COVID-19 pandemic, where delays in vaccine access highlighted the vulnerability of the continent.

Despite these challenges, President Ruto highlighted Africa’s research capacity, citing Kenya’s participation in COVID-19 vaccine trials as a testament to this potential.

H.E. Amb Minata SAMATE of

Ethiopia presented the African Union Health Strategy, emphasizing the urgent need to bolster Africa’s vaccination agenda to ensure broader access to vaccines and reduce preventable diseases.

This commitment aligns with the African Vaccine Manufacturing Accelerator (AVMA), a financing mechanism initiated by the Global Vaccine Alliance (GAVI) Board to enhance Africa’s vaccine manufacturing sector with a substantial investment of up to $1 billion.

The AVMA aims to accelerate the Partnerships for African Vaccine Manufacturing (PAVM), established by African Union Heads of State and Government in 2021, with the ambitious goal of manufacturing 60% of vaccines in Africa by 2040.

Aamal Medical and Austco Healthcare partner to modernize healthcare in Qatar

QATAR - Aamal Company Q.P.S.C. has announced a new strategic alliance between its wholly owned subsidiary, Aamal Medical, and Austco Healthcare to enhance patient care and healthcare worker communication in Qatar.

This collaboration marks a significant stride for both entities as they endeavor to enhance healthcare outcomes and deliver state-of-the-art patient care to the market.

With over 50 years of combined expertise, Aamal Medical specializes in delivering comprehensive healthcare solutions and services, ranging from medical equipment and consulting to IoMT (Internet of Medical Things) connectivity, medical consumables, maintenance services, and large-scale healthcare project execution.

By joining forces with Austco Healthcare, renowned for its innovative healthcare communication solutions

developed over three decades, Aamal Medical aims to revolutionize care delivery in Qatar.

The alliance will introduce cuttingedge nurse call systems, clinical workflow solutions, and patient engagement technologies, reshaping the healthcare landscape in the region and benefiting both patients and medical practitioners alike.

Mr. Gokhan Ozkan, General Manager of Aamal Medical, expressed his enthusiasm for the collaboration, emphasizing Aamal Medical’s dedication to partnering with industry leaders to offer competitive solutions and uphold the highest standards of care.

Similarly, Mr. Lee Lister, General Manager for the Middle East and Africa at Austco Healthcare, highlighted the alignment of the collaboration with their core values of innovation, quality, and customer-centricity.

He underscored their joint mission to leverage their expertise to empower healthcare providers, enhance patient experiences, and drive better health outcomes for the people of Qatar.

THE ALLIANCE WILL INTRODUCE CUTTING-EDGE NURSE CALL SYSTEMS, CLINICAL WORKFLOW SOLUTIONS, AND PATIENT ENGAGEMENT TECHNOLOGIES

HOSPITALS

Burjeel Holdings opens its new state-of-theart Head and Neck Institute

UAE - Burjeel Holdings has inaugurated the new Burjeel ENT Head and Neck Institute at its flagship facility, Burjeel Medical City, in Abu Dhabi, UAE.

The institute offers comprehensive and advanced services in Otolaryngology (ENT) – Head and Neck Surgery, including specialized treatments such as otology-neurotology, rhinology, and pediatric otolaryngology.

With a focus on patient-centric care and engagement, the institute aims to provide world-class healthcare to patients in the MENA region.

Additionally, a Thyroid Parathyroid Center has been established as part of a multidisciplinary collaboration with the University of Kansas Medical Center, USA, to deliver advanced treatments for

MANUFACTURING

thyroid-parathyroid disorders.

The launch ceremony was attended by distinguished guests, including Her Excellency Dr. Bushra Al-Mulla, Director General of the Family Welfare Authority, and Mr. John Sunil, Group CEO of Burjeel Holdings, among others.

Last December, Burjeel teamed up with KEZAD Communities, a leader in integrated community solutions under KEZAD Group to build a healthcare clinic for the residents of Razeen 3 and 4 complexes.

The collaboration will enable the availability of timely and proficient care for residents, in particular thousands of residents will acquire fast and efficient primary healthcare at their doorstep.

BioNTech boosts cell therapy manufacturing with Autolus partnership

GERMANY - BioNTech has formed a strategic partnership with Autolus Therapeutics to enhance its cell therapy capabilities, marking a significant investment of up to US$250 million in Autolus.

This collaboration grants BioNTech licensing opportunities, including royalties on sales of Autolus’ obe-cel CAR-T therapy pending FDA approval.

BioNTech also gains access to Autolus’ manufacturing capacity,

facilitating the advancement of its BNT211 cell therapy for cancer, which is undergoing a pivotal Phase 2 trial.

The partnership aims to accelerate the development and commercialization of cell therapies, with BioNTech benefiting from financial backing and Autolus gaining access to critical supply infrastructure.

Additionally, BioNTech will purchase US$200 million of Autolus’ shares and have representation on Autolus’ board.

This investment will support Autolus’ operations and research efforts, furthering its development goals.

This collaboration underscores BioNTech’s commitment to exploring strategic partnerships and investments in promising biotech companies, following its success with the COVID-19 vaccine collaboration with Pfizer and previous ventures into antibody-drug conjugates and cancer drugs.

Ethiopia unveils comprehensive US$113M project to bolster pandemic preparedness

ETHIOPIA—The Ethiopian government has launched the Ethiopian Pandemic Multi-Sectoral Prevention, Preparedness, and Response Project (EPPR) to enhance the country’s defenses against pandemics.

With a focus on surveillance, laboratory systems, and One Health workforce development, the threeyear project aims to bolster Ethiopia’s pandemic prevention, readiness, and response capabilities.

Supported by a US$50 million grant from the Pandemic Fund and additional US$63 million co-financing, the EPPR involves collaboration among key stakeholders, including the Federal Ministry of Health (FMOH), Ministry of Agriculture (MoA), Ethiopian Public Health Institute (EPHI), Armauer Hanson Research Institute (AHRI), Animal Health Institute (AHI), WHO, UNICEF, FAO, and others.

The project aligns with national health strategies and demonstrates a commitment to comprehensive pandemic prevention.

Through effective coordination and strategic planning, the EPPR seeks to strengthen Ethiopia’s resilience to future pandemics, enhance health systems, and address various public health challenges exacerbated by climate change.

Key activities include workforce training, laboratory system improvement, and border surveillance enhancement, all contributing to Ethiopia’s pandemic prevention and response efforts.

JULY 18-20, 2024 | Sarit Expo Centre, Nairobi, Kenya

The Africa Hospitals Expo (formerly Africa Health Expo) will bring together visitors and delegates from Africa and across the World to discover the latest in healthcare delivery services from leading local, regional and international hospitals and other healthcare and wellness providers to an audience from Kenya, Eastern Africa and Africa at large.

Look forward to engaging with leading specialty hospitals, multispecialty hospital chains, wellness and care centres plus providers of the latest personal health and wellness products and services from Africa and beyond.

Plan to attend the highly-engaging clinical talks that will be addressed by professionals and consultants in the healthcare sector in Africa.

CONTACT US:

info@fwafrica.net

+254 725 343 932

www.africahospitalsexpo.com

Mubadala acquires KELIX bio to bolster UAE’s life sciences sector

UAE - Mubadala Investment Company has acquired KELIX bio, a specialty pharmaceutical business focused on delivering complex generics across emerging markets.

This acquisition aims to strengthen the UAE’s position in the global life sciences sector and enhance its pharmaceutical infrastructure.

KELIX bio, formed as a pan-African biopharmaceutical platform, operates in six countries and has revenues exceeding US$150 million.

The acquisition aligns with Mubadala’s goal of economic diversification and improving healthcare outcomes in the UAE.

Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala’s UAE Investments Platform, emphasized the acquisition’s role in accelerating the nation’s economic diversification through portfolio companies and national champions.

He highlighted the partnership’s potential to deliver long-term socioeconomic returns, including improved healthcare, drug security, job creation, and GDP impact.

Ismail Ali Abdulla, Head of UAE Clusters at Mubadala’s UAE Investments Platform, reiterated Mubadala’s commitment to enhancing community well-being through strategic healthcare investments.

He emphasized the goal of empowering the UAE’s healthcare infrastructure and ensuring wider access to life-saving treatments for all citizens through KELIX bio’s capabilities.

These agreements build on Mubadala’s efforts to establish an Abu Dhabi-based national pharmaceutical champion, enhancing the UAE’s pharmaceutical infrastructure, addressing prevalent diseases, reducing healthcare expenditure, strengthening drug security, and advancing towards a resilient, knowledge-based economy.

Indian Immunologicals Limited injects over US$84M into vaccine manufacturing plant

INDIA – Indian Immunologicals Limited (IIL) is investing approximately Rs 700 crores (US$84.19 million) in a new greenfield veterinary vaccine manufacturing plant in Hyderabad State, India.

This investment is expected to create over 750 direct and indirect jobs. The plant will feature a BSL3 facility for drug substance manufacturing and fillfinish capability for producing Foot and Mouth Disease (FMD) Vaccine and Foot and Mouth Disease + Haemorrhagic Septicaemia Vaccine.

Dr. K Anand Kumar, Managing Director of IIL, emphasized the company’s exponential growth and plans for additional investments in

HOSPITALS

infrastructure within India and in emerging geographies like Africa.

The funding will enhance IIL’s capabilities to develop tools for disease control and eradication in India and beyond.

As a subsidiary of the National Dairy Development Board, IIL is a market leader in veterinary and human biologicals in India, with the new facility expected to manufacture FMD vaccines in Hyderabad’s Genome Valley.

The facility, with a capacity of 150 million doses per annum, is part of IIL’s commitment to innovation and collaboration in vaccine development, supported by partnerships with national and international research institutes.

AFC to build AMCE Abuja Medical Center with US$40M investment

NIGERIA - Africa Finance Corporation (AFC) has pledged a substantial investment of up to US$40 million to construct the African Medical Centre of Excellence (AMCE) Abuja hospital in Nigeria, in collaboration with Africa Export-Import Bank (Afreximbank) and King’s College Hospital in London, UK.

This investment comes at a crucial time for Africa’s healthcare sector,

which faces significant infrastructure deficiencies and a shortage of skilled medical professionals.

The AMCE Abuja project aims to address these challenges by specializing in cancer, cardiology, and haematology while also focusing on research, education, and development.

The initiative, launched at the AMCE African Health Forum in Abuja, seeks to reduce medical tourism by providing world-class healthcare services locally.

The construction of the 500-bed hospital, set to open in 2025, is expected to create thousands of jobs, train medical professionals, and provide cuttingedge care to hundreds of thousands of patients in Nigeria and beyond.

AFC’s collaboration with Afreximbank and King’s College Hospital underscores a commitment to bridging Africa’s healthcare infrastructure gap and fostering sustainable development on the continent.

DISEASE

India tests first-ever human-derived TB Vaccine

INDIA - Bharat Biotech, a leading biotechnology company in India, is conducting clinical trials for MTBVAC, a live-attenuated tuberculosis vaccine developed in collaboration with Biofabri.

The trials, including safety, immunogenicity, and efficacy assessments, are pivotal, especially in a country like India with a high burden of tuberculosis cases.

The primary objective is to assess the immunogenicity and efficacy of MTBVAC when administered intradermally to infants on the first day of life.

Bharat Biotech has secured exclusive global manufacturing rights for this live

PHARMACEUTICALS

attenuated vaccine, targeting newborns, adolescents, and adults.

MTBVAC aims to offer improved efficacy compared to the existing BCG vaccine.

Esteban Rodriguez, CEO of Biofabri, emphasized the significance of testing MTBVAC in adults and adolescents in India, a country accounting for 28% of the world’s TB cases.

Dr. Krishna Ella, Executive Chairman of Bharat Biotech, expressed his honor in partnering with BioFabri, highlighting the noble effort to innovate TB vaccines.

MTBVAC has achieved several milestones, including completing a Phase 2 dose-finding trial and initiating

a Phase 3 clinical trial in newborns in 2023. The Phase 3 trial, partially funded by the European Union, compares MTBVAC with the current BCG vaccine.

AbbVie strikes US$713M monoclonal antibody deal with OSE Immunotherapeutics

USA – AbbVie and OSE Immunotherapeutics have forged a partnership and licensing agreement for the latter’s monoclonal antibody, OSE230, in a deal valued at up to US$713 million.

OSE-230 targets the G-Protein coupled receptor (GPCR) known as ChemR23. The treatment, currently in the preclinical development stage, holds promise for reducing persistent inflammation and modifying neutrophil and macrophage activity.

Per the terms of the collaboration agreement, AbbVie will make an upfront payment of US$48 million for the therapy’s exclusive worldwide license. Moreover, OSE stands to receive tiered royalties on net sales and milestonebased payments worth up to US$665 million.

OSE Immunotherapeutics is actively collaborating with other pharmaceutical entities, advancing multiple monoclonal antibody candidates, including BI 765063/OSE-172 and BI 770371 with

Boehringer Ingelheim, and FR104/VEL101 with Veloxis Pharmaceuticals.

In a Phase I trial (NCT05249426), BI 765063 is under evaluation in combination with various cancer medicines, including chemotherapy, Boehringer’s ezabenlimab, BI 836880, and Eli Lilly’s Erbitux (cetuximab).

This collaboration highlights AbbVie’s commitment to expanding its antibody treatment portfolio, following recent partnerships and acquisitions in the field.

Meanwhile, AbbVie has recently expanded its portfolio in antibody treatments, teaming up with BigHat Biosciences in December 2023 to discover and develop antibody treatments for neurological and oncological diseases.

In November 2023, AbbVie announced its plans to acquire ImmunoGen for US$10.1 billion. A central aspect of the deal was the antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine-gynx).

NEST360 Alliance expands efforts to reduce neonatal mortality in Africa

ETHIOPIA – The NEST360 Alliance, a coalition of clinical, technological, and public health professionals, has received a substantial investment of US$65 million to expand its efforts in reducing neonatal mortality across Africa.

Collaborating with governments, the alliance aims to strengthen health systems through innovative technology, education, and policy resources.

Funding from organizations like the

Bill & Melinda Gates Foundation and the ELMA Foundation will be instrumental in addressing the high rates of neonatal mortality in Sub-Saharan Africa, where over 1.1 million infants die annually from preventable causes.

The initiative seeks to reduce the region’s high newborn mortality rates and aims to halt unnecessary infant deaths by 2030, aligning with the United Nations’ Sustainable Development Goals.

By implementing a systemschange approach to optimal infant care, the alliance focuses on addressing multiple clinical needs, ensuring the availability of appropriate equipment, and implementing national policies to support overall care.

In Ethiopia, the alliance builds on national-level efforts called Saving Little Lives, with a goal to expand its reach to 144 implementing hospitals in five major countries.

Through engagement with African governments and stakeholders, the initiative aims to initiate long-term reform and improve the quality of care for newborns across the continent.

This international collaboration involves 22 top institutions and organizations, including universities, research institutes, and health technology centers, to drive impactful change in neonatal healthcare delivery.

Max Healthcare expands India footprint with acquisition of Alexis Multi-Speciality hospital

Analysts believe that HCG’s market potential and growth trajectory make it an attractive investment opportunity for EQT, TPG, and KKR. HOSPITALS

INDIA - Max Healthcare Institute Ltd has successfully acquired a 99.9% stake in Alexis Multi-Speciality Hospital Pvt Ltd for Rs 412 crore (US$49.62 million), expanding its presence in Western and Central India.

Alexis Multi-Speciality Hospital has been rebranded as Max Super Speciality Hospital, Nagpur, post-acquisition, integrating both entities.

Established in 2016, Alexis Hospital is renowned for providing comprehensive tertiary care services, including organ transplant, oncology, neurology, cardiology, gastroenterology, and diagnostics.

Max Healthcare’s Chairman and Managing Director, Abhay Soi, sees this acquisition as a significant

milestone in the company’s growth journey, emphasizing its commitment to delivering exceptional healthcare services.

In another development, EQT, TPG Capital, and KKR are reportedly considering acquiring a controlling stake in Healthcare Global Enterprises (HCG), a leading Bengaluru-based specialty cancer hospital chain, from CVC Capital.

CVC, currently holding around 60.41% stake in HCG, is exploring a potential sale amid heightened consolidation in Asia’s healthcare sector.

HCG, with its extensive network of cancer hospitals across India, has established itself as a key player in cancer care treatment, driven by strong brand equity and strategic initiatives.

ALEXIS HOSPITAL IS RENOWNED FOR PROVIDING COMPREHENSIVE TERTIARY CARE SERVICES, INCLUDING ORGAN TRANSPLANT, ONCOLOGY, ETC

PureHealth completes acquisition of UK’s hospital operator Circle Health Group

UK – PureHealth has finalized its strategic acquisition of Circle Health Group, an independent operator of hospitals based in the United Kingdom, in a deal valued at US$1.2 billion before debt.

This acquisition marks PureHealth’s strategic expansion into the UK healthcare market as part of its broader global growth strategy.

Hamad Al Hammadi, Chairman of PureHealth, expressed satisfaction with the swift completion of the acquisition, highlighting the company’s operational

HEALTHCARE DELIVERY

excellence and adaptability.

The agreement, initially struck in May 2023, saw PureHealth acquiring 100% ownership of Circle Health Group’s network of advanced hospitals.

This move signifies PureHealth’s commitment to advancing healthcare and longevity globally, alongside fostering partnerships and enhancing patient care.

By gaining control of Circle Health Group’s portfolio, which includes specialties like Orthopaedics, Oncology, and Neurosurgery, PureHealth solidifies its position as a leading global healthcare player.

The acquisition aligns with PureHealth’s vision of providing worldclass medical care with the highest international standards.

The company aims to invest in scientific advancements and healthcare infrastructure, reflecting its dedication to revolutionizing healthcare services worldwide.

Kenya’s Revital acquires WHO prequalification for AD Syringes

KENYA - Revital Healthcare EPZ, East Africa’s largest auto-disabled syringe manufacturer based in Kenya, has achieved World Health Organization (WHO) Prequalification for its autodisabled (AD) syringes.

This recognition ensures that Revital’s products meet global quality and safety standards, enhancing access to essential health goods and improving health outcomes.

WHO prequalification is highly regarded and serves as a symbol of safety, quality, and efficacy in the healthcare sector.

Revital’s AD syringes, designed to prevent reuse and increase vaccine safety, align with Africa CDC’s goal of promoting local manufacturing and

innovation in healthcare products.

As the first company in East and Central Africa to produce medical devices, Revital exemplifies Africa’s capacity to provide critical medical supplies, including during the COVID-19 pandemic.

The establishment of continental agencies and coordination bodies, such as the Partnership for African Vaccine Manufacturing, further supports Africa’s vision of vaccine selfsufficiency by 2040.

However, achieving this goal requires collaborative efforts and effective coordination among stakeholders to ensure sustainable markets and strong health systems across the continent.

Tanzania implements Global Action Plan for neurological disorders

TANZANIA - Tanzania has become the first African nation to implement the Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031 (IGAP), partnering with the World Health Organization (WHO) to address epilepsy and Parkinson’s disease.

Through collaboration with local stakeholders and WHO, Tanzania is focusing on improving medication access and developing interventions.

Dr. Charles Sagoe-Moses, WHO Representative in Tanzania, commends the country’s efforts and highlights the impact of neurological disorders.

Tanzania has conducted workshops and meetings to assess progress and ensure continuity of action.

Dr. Omary Ubuguyu, Assistant Director for NCDs at the Ministry of Health, emphasizes Tanzania’s commitment to collaborating with WHO to ensure access to affordable medications for neurological illnesses, with a focus on population-wide access to necessary services and support.

Significant milestones include establishing a national coordination committee, providing technical support, and integrating medicines for neurological disorders into the National Health Insurance Fund package for 2024.

Despite progress, gaps in diagnosis and treatment persist, underscoring the importance of well-prepared health systems.

Tanzania’s initiatives contribute to IGAP’s goal of improving access to essential medicines and technology for managing neurological disorders by 2031.

IVI opens office in Kenya to support research and development

KENYA – The International Vaccine Institute (IVI), a non-profit organization dedicated to the discovery, development, and delivery of safe, effective, and affordable vaccinations, has established a Country and Project Office in Kenya to support research and development efforts.

This office will oversee the Advancing Vaccine End-to-End Capabilities (AVEC) program in Africa, along with partnerships with local entities like the Kenya BioVax Institute.

The AVEC Africa initiative, endorsed by IVI’s Board of Trustees, aims to strengthen vaccination ecosystems in the region through grassroots publicprivate partnerships.

This approach, supported by African Heads of State including Kenya’s President, emphasizes tailored training and collaboration to build sustainable vaccine capabilities.

Dr. Jerome Kim, IVI’s Director General, highlighted the significance of leveraging IVI’s experience and networks across Africa to enhance vaccine sector coordination and skill development.

Dr. Michael Lusiola, CEO of Kenya BioVax Institute, noted that the IVI AVEC Project Office will support local vaccine production and collaborate with IVI’s Regional Office in Rwanda to advance vaccine research and development efforts.

The initiative began with a Memorandum of Understanding between IVI and the Africa CDC in November 2022, aligning with the Africa CDC’s goal of achieving vaccine self-sufficiency by 2040 through collaborations like the Partnerships for African Vaccine Manufacturing project.

MERGER & ACQUISITION

Bristol Myers buys RayzeBio for US$4.1B to bolster radio-pharmaceutical portfolio

USA— Bristol Myers Squibb (BMS) has finalized its acquisition of RayzeBio, a clinical-stage radiopharmaceutical company, for US$4.1 billion, following the signing of an agreement in December 2023.

This acquisition introduces a pipeline of radiopharmaceutical therapeutics (RPTs) to BMS, including the lead program RYZ101, targeting somatostatin receptor (SSTR)2, which is overexpressed in certain types of cancer.

RYZ101 is currently undergoing Phase III clinical trials for individuals with SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and Phase Ib trials for extensive stage small cell lung cancer (ES-SCLC). Encouraging interim data from the Phase Ib trials demonstrates both tolerability and efficacy.

Additionally, the acquisition includes an RPT manufacturing facility set to begin operations in the first half of 2024.

BMS CEO Chris Boerner expressed enthusiasm for the transaction, highlighting the strategic expansion of BMS’s oncology pipeline beyond immunotherapy.

He emphasized the potential of RPTs

as a rapidly growing treatment modality and the collaborative efforts with RayzeBio’s team to advance preclinical and clinical programs for the benefit of patients globally.

RayzeBio’s acquisition follows BMS’s strategic collaboration with VantAI, a company specializing in generative AIenabled drug discovery.

This partnership combines VantAI’s geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to innovate molecular glues.

THIS ACQUISITION INTRODUCES A PIPELINE OF RADIOPHARMACEUTICAL THERAPEUTICS (RPTS) TO BMS, INCLUDING THE LEAD PROGRAM RYZ101

PHARMACEUTICALS

Novartis to acquire MorphoSys for US$2.9B to bolster oncology portfolio

GERMANY – Novartis, a pharmaceutical corporation based in Switzerland, is set to acquire MorphoSys in a cash acquisition agreement worth US$2.9 billion, aiming to bolster its oncology pipeline.

The acquisition will include cancer therapies pelabresib (CPI-0610) and tulmimetostat (CPI-0209), enhancing Novartis’s portfolio.

Tulmimetostat, an enhancer of zeste homolog 1 and 2 (EZH1/EZH2) protein, is an early-stage therapeutic candidate being evaluated in a Phase I/II study (NCT04104776) for advanced solid tumours and lymphomas.

Pelabresib is on the other hand a selective, small molecule bromodomain and extra-terminal domain (BET) inhibitor, designed to downregulate signals involved in myelofibrosis disease pathways and promote anti-tumour activity.

PARTNERSHIPS

MorphoSys secured pelabresib, with a US$1.7 billion takeover from U.S. cancer specialist Constellation Pharma, in the hopes of setting a new treatment standard.

In December, pelabresib met its latestage primary study goal and all four hallmarks of disease in myelofibrosis, when used in combination with ruxolitinib, a class of drugs called JAK

inhibitors.

Concurrently, Incyte acquired global rights to MorphoSys’ tafasitamab, highlighting MorphoSys’s strategic focus on offloading its pipeline assets.

This acquisition grants Incyte complete control over tafasitamab’s development and commercialization worldwide, marking a significant shift in their collaborative efforts.

KEMRI secures US$18.81M grant from JICA for advanced biotechnology training facility

KENYA – The Kenya Medical Research Institute (KEMRI) has inked a Memorandum of Understanding (MOU) with the Japanese government through JICA, which is expected to enhance the KEMRI’s Laboratory Expansion Project. President Ruto’s visit to Japan

witnessed the signing of this MOU, securing a grant of KES 3 billion (US$18.81 million) for the establishment of a cutting-edge biotechnology training facility.

This initiative, crucial for achieving the Government’s Universal Health Coverage (UHC) agenda, underscores Japan’s longstanding support for KEMRI’s research endeavors.

The facility, equipped with advanced laboratories and equipment, will bolster disease surveillance, pathogen identification, and the development of medical products critical for addressing biothreats and pandemics.

KEMRI’s designation as a national strategic institution highlights its pivotal role in spearheading biotech research and development, contributing

to enhanced health and well-being in Kenya and the region.

Prof. Elijah Songok, Acting Director General of KEMRI, lauded this collaboration, expressing gratitude to President Ruto and the Japanese government for their commitment to advancing healthcare research and capacity building.

Meanwhile, KEMRI recently launched a US$70,000 (KES 10.5 million) mobile morgue to expand its research operations on child mortality among children under the age of five.

This is KEMRI’s first mobile mortuary service in Africa, and it will assist in a research study that will investigate the causes of death in Siaya and Kisumu counties as part of the Child Mortality Studies.

Prof. Richard Lesiyampe succeeds Dr. Rae as JOOTRH CEO

KENYA — Prof. Richard Lesiyampe, a former agricultural principal secretary, has been appointed CEO of Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), succeeding Dr. George Rae, who led the hospital for five years.

Dr. Rae will now oversee resource mobilization for the Department of Medical Services Public Health and Sanitation at the County headquarters.

This announcement was made Dr. Gregory Ganda, County Health Executive, who noted that the new CEO will take over to deliver the second phase of the county’s health transformation, which he is to take on February 22, following his appointment by Kisumu Governor Anyang Nyong’o.

Prof. Lesiyampe’s fifteen-year tenure working with the Kenya Wildlife Service was marked by innovation and progress before he joined Kenyatta National Hospital as CEO, where he steered the facility towards excellence.

His subsequent appointments as Permanent Secretary in the Ministry of Environment and the Department of Agriculture-Crop Development solidified his reputation as a leader who could not only dream big but also translate those dreams into tangible results.

Healthcare innovator Varsha Vala takes helm at Medihelp

SOUTH AFRICA — Varsha Vala has been named as Medihelp Medical Scheme’s next principal officer, beginning March 1, 2024.

Vala began her career as a pharmacist and now has over 25 years of expertise in healthcare, managed care, and design thinking.

Her achievements in managed care include establishing the country’s first comprehensive managed care solution based on risk stratification and a holistic

health and well-being paradigm.

Before her appointment, Vala served as a leading executive for digital and managed care at the Professional Provident Society (PPS).

While welcoming her, Chris Klopper, chairperson of the Medihelp Board of Trustees, expressed his excitement in having Varsha join the Medihelp team, noting that she had the expertise and abilities that the scheme requires now and in the future.

Klopper emphasized that Varsha’s extensive knowledge will be extremely beneficial in tackling this challenge.

Her outcomes-focused approach will also assure effective risk management for schemes that want to keep their claims ratio low and improve their solvency.

Professor Moffat Nyirenda appointed Director of the Medical Research Council in Uganda

UGANDA — Professor Moffat Nyirenda, has been appointed Director of the Medical Research Council.

Prof. Nyirenda will succeed Prof. Pontiano Kaleebu, who has led the unit for the previous 13 years, on April 1, 2024.

The appointment was made after an elaborate recruitment process including public health experts from several African and UK institutes, which was overseen by a professional executive search agency.

His distinguished career has ranged from molecular medicine to clinical and public health research, including studies into noncommunicable diseases such as diabetes, obesity, and hypertension.

During Prof. Kaleebu’s tenure, Prof. Nyirenda oversaw several achievements, including expanding the unit’s research competence beyond HIV into other viral pathogens, vaccine research, and noncommunicable diseases, and educating many young scientists as the next generation of health leaders.

Prior to assuming this position, Prof Nyirenda was Deputy Director of the MRC/UVRI & LSHTM Uganda Research Unit.

He also worked at the University of Edinburgh as part of the MRC Clinician Scientists Fellowship program

Dr. Ayesha Chaudhary takes the reins as India Director of WomenLift Health

INDIA — Dr. Ayesha Chaudhary assumes the role of India Director at WomenLift Health, aiming to advance women leaders in the health sector.

As the new director, Dr. Chaudhary is expected to build on the significant momentum achieved in the organization’s programs and strategic initiatives in the country.

Her strategic vision aligns with the organization’s commitment to diversity and empowering women.

In her address, Dr. Ayesha said: “At WomenLift Health, we intend to drive a mindset and behavior change, empower individuals, institutions, and societies to reimagine leadership through innovation, and use effective leadership to further impact global health outcomes.”

Dr. Chaudhary’s previous roles include serving in the Indian government and co-founding a med-tech startup.

Her appointment coincides with WomenLift Health’s expansion plans and partnership initiatives, including the Women Leadership in STEM program with BIRAC.

The organization aims to equip women leaders with tools and resources for impactful leadership through its India Leadership Journey.

Corteria Pharmaceuticals picks Dr. Mark Pruzanski as the board chair

FRANCE — Corteria Pharmaceuticals (Corteria) has tapped Dr. Mark Pruzanski as the new Chairperson of the biopharmaceutical company’s Board of Directors.

Dr. Pruzanski replaces Thierry Laugel, Managing Partner at Kurma Partners, who remains a member of the board.

He brings over 30 years of experience

in drug development and biotechnology leadership, having previously served as CEO of Versanis Bio and Intercept Pharmaceuticals.

With a focus on developing transformative therapies for heart failure and obesity, Corteria aims to leverage Dr. Pruzanski’s strategic vision and expertise.

“His strategic vision, outstanding leadership, and passion for innovation make Mark a valuable addition to Corteria as we continue our mission to advance innovative therapeutic solutions for heart failure and obesity,” stated Philip Janiak, Founder and Chief Executive Officer of Corteria Pharmaceuticals.

Dr. Mark expressed his readiness to work with Philip Janiak and the other members of the board to help ensure the biopharmaceutical company’s future success.

Gavi, the Vaccine Alliance names Dr. Sania Nishtar as CEO

SWITZERLAND — Dr. Sania Nishtar has been named the new Chief Executive Officer of Gavi, the Vaccine Alliance, effective March 18, 2024, succeeding David Marlow, who held the office on interim basis.

Dr. Nishtar brings a wealth of experience in global public health, having chaired Gavi’s Evaluation Advisory Committee and served as an independent member of the Gavi Board.

She has held leadership roles in civil society, international organizations, and the Pakistani government, advocating for health reform and women’s and children’s health.

The announcement of Dr. Nishtar’s appointment coincides with Gavi’s fifth five-year strategic plan, which will expire at the end of 2025.

Dr. Nishtar aims to prioritize fundraising and support Gavi’s strategic plan to reach millions of children with life-saving vaccines.

Dr. Nishtar said: “I look forward to working with Gavi’s talented staff and skilled Alliance partners to ensure Gavi reaches hundreds of millions of children in lower-income countries with life-saving vaccines against deadly and debilitating diseases.”

Her appointment is seen as crucial for Gavi’s mission of protecting future generations and addressing global health challenges.

MERCY SHIPS

A voyage to wellness: Aboard Mercy Ships, the World’s Largest Floating Hospital

By JACKIE MUINDE

In 1978, a dream set sail. Don and Deyon Stephens, from Switzerland, envisioned a modern hospital bringing free surgery and medical care to the world’s most impoverished communities. But instead of a traditional, landlocked clinic, their plan was for something mobile that could navigate between countries. Thus, the idea of a hospital ship was born.

Their first vessel was the Victoria, a retired 11,700-ton luxury liner that once traversed the route between Venice and Hong Kong. Acquired for a its scrap value of US$1 million, this nine-deck behemoth underwent a four-year transformation into a state-of-the-art medical center. In 1982, christened the MV Anastasis, she embarked on her maiden voyage to Africa, carrying a crew of 350. The Anastasis became the first of four Mercy Ships that have treated over five million people to date.

The organization, Mercy Ships, has blossomed into a respected international charity rooted in Christian values. They operate the world’s largest non-governmental hospital ships, delivering hope and healing across Africa. Beyond surgical care and training, Mercy Ships offers a comprehensive approach, encompassing community development projects, health education initiatives, mental health programs, agricultural support, and palliative care.

“The faces of leadership change, and nations evolve,” says Dr. Juliette M. Tuakli, Mercy Ships’ Diplomatic Ambassador for Africa, in an

exclusive interview with The Healthcare Middle East and Africa Magazine. “Yet, the fundamental need for hope and healing persists. Mercy Ships strives to address this enduring need, embodying the 2,000-year-old model of Jesus: offering solace and restoring health.” Currently, their reach extends to all 54 African nations.

Originally affiliated with YWAM (Youth with a Mission), Mercy Ships became an independent organization in 2003. While their legacy involves transforming retired vessels into floating hospitals, 2021 marked a turning point with the launch of the Global Mercy, the world’s first purpose-built hospital ship, joining their impressive fleet.

DELIVERING WORLD-CLASS CARE TO THOSE WHO NEED IT MOST

Africa, home to roughly one-third of the world’s population, faces a critical healthcare disparity. While an estimated 330 million surgical procedures occur globally each year, only 6% happen in Africa. Often, these procedures are performed in unsafe environments. Mercy Ships tackles this imbalance by delivering advanced healthcare directly to those who need it most.

“We operate two hospital ships, the Africa Mercy and the recently launched Global Mercy,” explains Dr. Juliette”These are the world’s largest non-governmental hospital ships, specifically dedicated to serving the African continent. In a typical year, over 1,500 volunteers from across the globe serve on both our vessels.”

DR. JULIETTE , MERCY SHIP’S

DIPLOMATIC

AMBASSADOR FOR AFRICA

The Africa Mercy boasts a lower deck outfitted with five operating theaters, an 82-bed recovery ward, a CT scanner, an X-ray machine, and a laboratory. Above deck, 126 cabins provide comfortable living quarters for a crew of more than 400, including families, couples, and individuals. Amenities include a daycare center, a fully accredited K-12 academy, a library, laundry facilities, a convenience store, a restaurant, a gym, and even a donated Starbucks cafe. Additionally, a fleet of 28 vehicles supports Mercy Ships’ landbased operations.

The Global Mercy offers equally impressive capabilities. This state-of-the-art vessel features space for 200 patients, six operating rooms, a laboratory, general outpatient clinics, dental and eye care facilities, and dedicated training areas. The expansive hospital decks encompass 7,000 square meters and house the latest training equipment. When docked, the ship can accommodate up to 950 people, including a global crew and volunteer force.

The medical professionals aboard the Africa Mercy offer a wide range of life-changing surgeries and treatments. Procedures address complex issues like cleft lip and palate, cataracts, bowed legs, burn repair, dental care, and

obstetric fistula repair – a devastating childbirth injury. Mercy Ships’ care extends beyond physical ailments, alleviating the social stigma and isolation often experienced by those with disfiguring conditions.

“We meet the needs of all segments of society,” says Dr. Juliette. “From parents fearing the loss of a child to the young women left with early childbirth injuries and at risk of being ostracized by their communities due to lack of medical care. We also address the more common surgical, medical, and dental needs of populations with limited access due to financial constraints, geographical barriers, or other societal factors.”

A GLOBAL FORCE OF VOLUNTEERS KEEPS MERCY SHIPS AFLOAT

A dedicated volunteer force fuels Mercy Ships’ lifesaving mission. Over 3,000 volunteers from 60 nations typically donate their time and expertise each year, with roughly 1,500 local crew members joining from host countries during port visits. The arrival of the Global Mercy will more than double this volunteer base, significantly amplifying Mercy Ships’ impact.

The world’s largest non-governmental hospital ship, the Global Mercy, can accommodate a crew

and medical staff of 641. Mercy Ships welcomes volunteers for both short-term (weeks to a year) and long-term (over a year) commitments. Because the ship essentially functions as a selfcontained community, the volunteer skillset needs are diverse.

While surgeons, dentists, and nurses form the backbone of the volunteer force, opportunities abound for a wide range of specialties. Deckhands, carpenters, seamen, teachers, cooks, engineers, machinists, welders, plumbers, and electricians are all essential. Interestingly, Mercy Ships also seeks

agriculturalists, videographers, photographers, and writers.

It’s important to note that volunteers are responsible for covering their service costs, including crew fees, travel, passports, vaccinations, insurance, and personal expenses. Crew members typically raise funds from family, friends, and churches, or use personal savings. Mercy Ships’ FinACE program (Financial Accountability, Coaching and Encouragement) assists volunteers with budgeting, fundraising strategies, and provides tools like personalized webpages. Health insurance is mandatory for those serving more than two years, ranging from $30 to $300 per month depending on coverage. Emergency evacuation and repatriation insurance is included in the crew fee for shorter stints.

“The true criterion is the willingness to serve,” emphasizes Dr. Juliette. “If you have the heart to volunteer your time, talent, and resources to offer hope and healing, you’re eligible. There are no limitations based on religion or any other factor.”

CHAMPIONING ACCESS TO SAFE SURGERY ACROSS AFRICA

Two years ago, a pivotal moment unfolded in Dakar, Senegal. A three-day International Symposium brought together medical experts from 29 African nations. Following the event, a historic gathering of African Ministers of Health convened to chart a course towards wider and safer access to surgical care across the continent by 2030. This landmark initiative is known as the Safe Surgical Initiative.

“The vast disparity in access to safe surgery is a critical gap that Mercy Ships is actively working to address,” explains Dr. Juliette, Mercy Ships’ Diplomatic Ambassador for Africa. “The Safe Surgical Initiative, launched in Dakar two years ago, embodies this commitment. We advocate for its adoption by the African Union to ensure all African countries can not only sign on but also commit to delivering safe surgical care to their citizens.”

To reach a broader patient population, Mercy Ships is strategically expanding its reach. “Our operational approach

WE ADVOCATE FOR THE ADOPTION OF THE SAFE SURGICAL INITIATIVE BY THE AFRICAN UNION TO ENSURE ALL AFRICAN COUNTRIES COMMIT TO DELIVERING SAFE SURGICAL CARE TO THEIR CITIZENS.

DR. Juliette - Mercy Ships’ Diplomatic Ambassador for Africa.

42 YEARS IN NUMBERS

NUMBER OF YEARS MERCY SHIPS HAS BEEN IN OPERATION

has shifted towards a regional model, extending beyond the borders of a single host nation,” says Dr. Juliette. “This strategy allows us to significantly increase our impact, especially considering some neighboring countries are landlocked and lack maritime access. We’re forging partnerships to facilitate patient transportation from these countries to the ship for treatment.”

Dr. Juliette elaborates on the process of establishing a presence in a host country. “It begins with a formal invitation from a government,” she explains. “We then collaborate closely with the host country’s Ministry of Health to identify their most pressing surgical needs. This collaborative approach leverages our strengths to address those needs while simultaneously providing surgical and medical interventions onboard the ship.”

LEAVING A LASTING LEGACY

Mercy Ships, a non-profit dedicated to free medical care, has served Africa for over 30 years. Its mission began in 1991 when the MV Anastasis docked in Togo at the government’s request, offering free surgical services. Since then, Mercy Ships vessels have extended their reach to numerous African nations, including the Republic of Congo, Benin, Cameroon, Senegal, and Guinea. Togo and Sierra Leone have been the

biggest beneficiaries, welcoming Mercy Ships five and six times respectively.

Beyond immediate surgical, medical, and dental care, Mercy Ships invests in longterm solutions to strengthen local surgical infrastructure. Dedicated development teams collaborate with local leaders, governments, and health ministries to assess needs and design projects that foster a sustainable surgical ecosystem within partner hospitals.

“Our mission transcends goodwill,” emphasizes Dr. Juliette. “We are committed to ensuring the continuation of vital services after our departure. This isn’t a one-time intervention; it’s a long-term commitment. The renovated facilities provide a continuum of care and training opportunities. Furthermore, our dedicated communications team fosters and maintains the relationships that develop through these projects.”

PRIORITIZING INCLUSIVITY IN HEALTHCARE DELIVERY

Inclusivity is a growing area of focus for Mercy Ships. While many volunteers, particularly doctors, come from outside Africa, Dr. Juliette, Mercy Ships’ Diplomatic Ambassador for Africa, explains, “Patients often prefer to be treated by individuals who share their ethnicity and

DR. JULIETTE

DELIVERING A SPEECH

DURING THE GLOBAL MERCY ARRIVAL CEREMONY

language, or at least understand their cultural background. This fosters a trust and safety net for patients.”

Mercy Ships is actively addressing this by diversifying its volunteer base, with Dr. Juliette herself serving as a powerful example. “My qualifications are undeniable,” she says, “and I’ve never felt marginalized. Even when viewpoints differ, I feel my perspective is valued.” The organization’s medical training program further bridges the gap. Dr. Juliette reports, “A growing number of surgical trainers hail from the African continent itself.”

The COVID-19 pandemic did disrupt training to some extent, with certain procedures suspended to mitigate viral spread. However, Dr. Juliette highlights the success of virtual training for many staff members. “While COVID-19 limited access to in-person surgeries, virtual training continued seamlessly. As facilities reopened, we had a larger pool of well-trained personnel ready to serve in countries previously visited by Mercy Ships. Our direct patient care capacity may have been reduced, but our impact and technical capabilities remained strong.”

The West African College of Surgeons is considering accrediting Mercy Ships’ training programs, a move Dr. Juliette applauds. She believes this will incentivize African surgeons to adopt modern surgical techniques, aligning with Mercy Ships’ goal of promoting safe surgical access.

FUNDING AND BUILDING PARTNERSHIPS

Mercy Ships relies primarily on private donations, foundation

grants, and contributions from socially responsible corporations. Its national offices in Europe and the United States hold ongoing fundraising campaigns. Dr. Juliette expresses her deep appreciation for these dedicated supporters, who leverage their networks to raise funds for capital improvements and operational costs.

Notable contributions include a generous $18 million commitment from Michael and Susan Dell in 2022, and support from the MSC Foundation, a Swiss non-profit affiliated with the international shipping company MSC Group. Dr. Juliette also highlights the valuable partnership with Orange, a French telecommunications company, which significantly reduced patient transportation costs in Guinea. “This benefited both the patients and Mercy Ships tremendously,” she said. “Volunteering extends beyond financial contributions; time, talent, and treasure are all vital forms of support.”

Mercy Ships welcomes partnerships of all kinds, not just with medical personnel. Dr. Juliette emphasizes, “Everyone has skills, talents, and interests that can contribute to our mission. We encourage organizations, individuals, and companies to explore partnering with us.” The organization seeks expanded collaborations with institutions in the pharmaceutical and radiology fields, exploring partnerships for medication provision and facilitating specific procedures within allied medical facilities.Currently stationed in Sierra Leone and Madagascar, Mercy Ships remains steadfast in its mission of promoting good health and well-being across Africa. HCMEA

Medical Research Organizations in Africa

Medical research institutions are critical to understanding diseases, developing new treatments, and shaping healthcare’s future. This report, based on data from Elsevier, a Dutch academic publishing company, and Scimago Lab, a global information analytics firm, highlights the top 10 medical research organizations in Africa.

The ranking encompasses institutions from various sectors, including government, healthcare, universities, and private entities. It primarily considers the volume, impact, and quality of research output. Additionally, factors like patent applications, citations, website size, backlinks, and social media mentions are incorporated for comprehensive evaluation.

1 South African Medical Research Council

Country: South Africa

Established in 1969, the South African Medical Research Council (SAMRC) is devoted to promoting public health in South Africa through research, innovation, development, and technology transfer.

The institute’s research activities

include genetic research, the development of novel treatment regimens, vaccine development, diagnostic tools, and the development of new drugs and equipment. All these are aimed at reducing South Africa’s quadruple disease burden which includes maternity, neonatal, and child health, HIV/AIDS and tuberculosis, noncommunicable diseases, and interpersonal violence.

SAMRC was ranked 2027th overall in 2023, with individual rankings of 1081st in research, 4097th in innovation, and 1688th in societal rankings.

2

Kenya Medical Research Institute

Country: Kenya

The Kenya Medical Research Institute (KEMRI) has established itself as a leading force in human health research within the region over its four decades of operation. The institute actively engages in national disease surveillance, boasting rapid response capabilities for outbreaks like cholera, Chikungunya virus, H1N1 flu, yellow fever, Rift Valley fever, Ebola, and aflatoxicosis.

KEMRI’s research footprint extends across 14 centers, garnering recognition as a premier center of excellence in health research, both in Africa and globally. In 2023, it secured the secondbest research institute ranking in Africa, solidifying its significant contributions to the field.

On a global scale, KEMRI stood at 2,352nd. Its specific rankings include 1,183rd in research, 4,993rd in innovation, and 2,010th in societal rankings, demonstrating its comprehensive approach to tackling health challenges.

3

Centro de Investigacao em Saude da Manhica

Country: Mozambique

The Manhiça Health Research Center (CISM) in Mozambique stands as a well-established and influential research facility dedicated to the study of transmissible diseases . CISM focuses on addressing the primary sources of morbidity and mortality in Mozambique, including malaria, HIV/AIDS, tuberculosis, and bacterial infections.

In 2023, CISM was ranked as the third-best research centre in Africa. Globally, it held the 2224th position overall, indicating its impact on an international scale. The centre’s rankings include 1157th in research, 3961st in innovation, and 6553rd in societal rankings.

4

Uganda Ministry of Health

Country: Uganda

In Uganda, the Ministry of Health is a key governmental body in charge of healthcare leadership and management.

Its responsibilities include policy development and review, oversight of healthcare activities, engagement with development partners, strategic planning, resource mobilization, and health-related assistance to other government agencies.

In 2023, the Ministry of Health was ranked 2595th globally, with individual rankings of 1112th in research, 5402nd in innovation, and 5808th in societal rankings.

Medical Research Organizations in Africa

Groote Schuur Hospital

Country: South Africa

Groote Schuur Hospital (GSH) in Cape Town, South Africa, has a long history spanning over 85 years and is internationally renowned for its contributions to medical research, including the first successful human heart transplant.

The hospital, which also operates as a teaching hospital in cooperation with the University of Cape Town (UCT) Medical School, offers specialized services in a variety of medical fields, including trauma, neurology, cancer, and cardiovascular surgery. Notably, GSH is South Africa’s sole publicsector institution for transplantation.

The hospital was ranked 3943rd overall, 2733rd in research, 5240th in innovation, and 3973rd in social rankings in 2023.

National Institute for Medical Research

Country: Tanzania

The National Institute for Medical Research (NIMR) in Tanzania has been instrumental in advancing health research and improving the well-being of the Tanzanian community since its establishment in 1980.

NIMR mandates include conducting and promoting health research, exploring traditional medical practices, training local personnel in scientific research, monitoring and coordinating medical research within Tanzania and beyond, registering and applying medical research findings, and establishing systems for documenting and disseminating research information. Over the years, its operations have expanded and currently include 7 centres and 7 stations across Tanzania.

In 2023, NIMR was ranked as the sixth-best institution in Africa, showcasing its regional significance. Globally, it held the 3435th position overall. The institute was also ranked 1135th in research, 6030th in innovation, and 4989th in societal rankings.

Theodor Bilharz Research Institute

Country: Egypt

Egypt’s Theodor Bilharz Research Institute (TBRI) stands at seventh place among Africa’s leading medical research institutions. Founded in 1964 with assistance from Germany and named after renowned parasitologist Theodor Bilharz, TBRI focuses on advancing biomedical research and generating solutions for prevalent tropical diseases, particularly schistosomiasis and viral hepatitis.

Located in Giza Governorate’s Warrak district, TBRI also houses a 300bed hospital, signifying its commitment to both research and patient care. This integrated approach allows the institute to bridge the gap between research and practical healthcare applications.

Globally, TBRI ranked 5,565th overall in 2023, with specific rankings of 5,984th in research, 4,065th in innovation, and 8,044th in societal impact.

Country: Egypt

Established in 1977 and officially opened in May 1983 by President Mohamed Hosni Mubarak, Mansoura University’s Nephrology and Urology Center has played an important role in delivering superior medical services to Egyptian people as well as patients from Arab and African countries .

The center’s emphasis on renal diseases, urology, and kidney transplant procedures has propelled its status both in Africa and on the global stage. Globally, it ranks 5588th overall, 7068th in research, 3018th in innovation, and 8113th in societal rankings.

Country: Tunisia

Founded in 1893, the Institut Pasteur de Tunis has focused its research on infectious diseases, including viral, bacterial, and parasitic origins, as well as those transmitted by animals and vectors. Today, it plays a vital role in Tunisia’s healthcare system, conducting epidemiological and clinical studies, biomedical investigations, and research related to both human and animal health.

The institute’s strategic research and training programs address crucial public health concerns such as rabies, viral hepatitis, measles, enteroviral infections, coronavirus, papillomavirus infections, leishmaniasis, hydatidosis, tuberculosis, mycoplasmosis, and bovine theileriosis. Additionally, it contributes to vaccine and serum production to address Tunisia’s specific healthcare needs.

On a global scale, the institute has been recognized for its achievements, ranking 4,955th overall, 5,255th in research, 3,752nd in innovation, and 6,294th in societal impact.

Country: Egypt

The National Cancer Institute (NCI) in Cairo, Egypt, indeed has a significant and impactful history in the field of cancer care. Dating back to the 1950s, the NCI has undergone substantial expansion and development over the years, evolving into the largest cancer hospital in the Middle East with an impressive 550 beds.

In 2023, the NCI was ranked as the tenth-best research organization in Africa. It had an overall global ranking of 4823rd, showing its prominence in the international healthcare landscape. In terms of research, it was ranked 3772nd, highlighting its commitment to advancing cancer-related studies. In terms of innovation, it was ranked 5213th, showcasing its efforts in adopting cutting-edge technologies and treatment approaches. In societal rankings, the NCI was positioned at 6460th globally, reflecting its contributions to the well-being of society.

Nephrology and Urology Center

Institut Pasteur de Tunis

Cancer Institute

(KMA)

KENYA MEDICAL ASSOCIATION (KMA)

Championing Quality Healthcare and Doctor Welfare

By PAUL ONGETO

The Kenya Medical Association (KMA) stands as a cornerstone organization within the Kenyan healthcare landscape. Established in 1968, the association serves a dual purpose: advocating for the highest quality of medical care for the nation’s citizens while ensuring the well-being of its doctor members. Healthcare Middle East and Africa Team (HCMEA) had the pleasure of interviewing KMA President Dr. Simon Kigondu and CEO Dr. Brenda Obondo. The two provided rare insights into the workings of the KMA, the significant role it plays in shaping Kenya’s medical ecosystem, and why every medical officer should be part of association.

HCMEA: Thank you so much for joining us in this interview. Before we dig in, our readers would like to get to know you. Can you tell us a bit about yourselves?

DR. KIGONDU: My name isW Currently, I am the President of the Kenya Medical Association. I hold a diploma in IT and have pursued medicine at the University of Nairobi. After completing my undergraduate studies in 2000, I was posted to Machakos District Hospital for three years. Subsequently, I undertook postgraduate studies in obstetrics and gynecology at the University of Nairobi, completing in 2007. Following this, I served as a gynecologist at Isiolo District Hospital for five years, where I also held the roles of medical superintendent and District Medical Services Officer. Later, I moved to Muranga District Hospital and eventually to Kigumo SubCounty Hospital in 2020. Alongside my public sector roles, I have maintained a private practice,

currently operating as CEO of Exella Healthcare, specializing in obstetrics and gynecology.

DR. OBONDO: Thank you for having me. I am Dr. Brenda Achieng Obondo, and I serve as the Chief Executive Officer of the KMA. Before becoming CEO, I was a member of the KMA for many years, dating back to when I first started practicing medicine. I’ve always believed in actively participating in the association, as our strength comes from our members. A strong membership allows us to advocate for both doctors and the public. So, when the CEO position at the KMA became available, I felt compelled to apply. I understood the association and was passionate about its mission.

HCMEA: What led you to join the Kenya Medical Association?

DR. KIGONDU: I became involved as an intern, curious about what I could do as a young doctor. After completing my internship, I took over the Machakos division of KMA, serving as chairman from 2001 to 2003. During this time, we focused on recruitment and engagement, visiting hospitals to promote KMA and

encourage participation in its activities. A significant event that reinforced my involvement was during the 2001-2002 campaign period when medical camps were organized across the country. Participating in these camps, including a notable one in Kabarak, fueled my dedication to KMA. Since then, I’ve been actively involved, traversing the country to boost morale and engagement among members, attending meetings and conferences in different divisions.

DR. OBONDO: I began by joining the Young Doctors Network, eventually becoming one of its co-convenors. I’m also involved with my local division within the KMA. Through these experiences, I gained a deep understanding of the challenges faced by doctors in Kenya. While I now serve at a different level, I remain engaged through my divisional council and by mentoring young doctors in the advocacy and policy work we do.

HCMEA: Can you provide a brief history of the Kenya Medical Association (KMA) and its key milestones?

DR. KIGONDU: Certainly. The Kenya Medical Association traces its origins back to the British Medical Association Kenya Chapter before independence. In 1968, four years post-independence, it officially became the Kenya Medical Association. By 1975, it had transitioned into a company limited by guarantee. Over the years, KMA has expanded its reach by establishing branches in various regions, starting with the Coast Division and later including divisions in Kisumu, Eldoret, Nanyuki, Nakuru, Nyahururu, and others. Currently, KMA boasts 17 divisions nationwide.

HCMEA: What are the primary objectives and roles of the Kenya Medical Association?

DR. OBONDO: The Kenya Medical Association serves two main functions: advocating for the highest quality of healthcare in the country and ensuring the welfare of its members. These objectives are central to our mission as a professional association for doctors practicing in Kenya.

HCMEA: How is the Kenya Medical Association structured and governed?

DR. KIGONDU: At the core of KMA’s structure is the secretariat, known as the National Executive Committee, consisting of five elected officials: President, Vice President, Secretary, Vice Secretary, and Treasurer General. Elections

THE KENYA MEDICAL ASSOCIATION SERVES TWO MAIN FUNCTIONS: ADVOCATING FOR THE HIGHEST QUALITY OF HEALTHCARE IN THE COUNTRY AND ENSURING THE WELFARE OF ITS MEMBERS.

DR. Kigondu - President KMA

IN NUMBERS

NUMBER OF KMA DIVISIONS COUNTRYWIDE 17

for these positions occur every two years, with a possibility of renewal for one term. Additionally, convenors oversee thematic committees within the association, contributing to its governance.

These thematic committees play a vital role in addressing professional challenges and advancing healthcare delivery in the country. For instance, the HIV committee was instrumental in facilitating HIV treatment in the early 2000s. Through grants and training programs, they significantly contributed to the management of HIV, transforming healthcare practices. Currently, committees like the Managed Health Care Committee focus on issues such as universal health coverage and healthcare financing through the Social Health Insurance Fund, engaging with policymakers and providing guidance through memoranda and policy recommendations.

Other notable committees include the Reproductive Health Committee, which influences reproductive health policies, the Research and Ethics Committee, aiming to establish an Ethics Board to expedite research dissemination, and the Public Health Committee, pivotal in managing emerging health issues like COVID-19 and tobacco control. Examples of past contributions include policy documents on tobacco control and family

DR. KIGONDU SIGNING AN MOU WITH KENYA PAEDIATRIC RESEARCH CONSORTIUM TO WORK CLOSELY IN IMPROVING ADVOCACY FOR BETTER HEALTHCARE

planning adopted by the Ministry of Health.

As I had mentioned earlier, the Association is comprised of Divisions. These form the foundation upon which the KMA is built on. Initially, the number of doctors was limited, with only a few branches such as Nairobi and Coast. However, as the number of doctors increased due to more medical schools and graduates, the aim was to continuously expand and form new divisions. When there are enough doctors, typically around 25, they can establish a new division. Each division is managed by secretariat, led by the president and vice-president. The division employs staff depending on their needs, usually including an administrator to coordinate activities and recruit new members. Every three months, the National Executive Commitee visits a different division, engaging with members and addressing their concerns. This approach strengthens the association’s reach and ensures members feel connected to the leadership.

The Annual General Meeting is the top decision-making organ where members meet once every year to ratify decisions. This year, it will be held in Kisumu from April 24th to 27th. This event usually serves as a platform for members to come together, discuss important matters, and

participate in professional development activities.

HCMEA: What does the Kenya Medical Association do in terms of welfare for its members?

DR. KIGONDU: Certainly. Historically, the welfare aspect of the Kenya Medical Association involved providing advice on policy issues regarding healthcare management in the country. However, a significant transformation occurred in 1992. During that time, many doctors resided in the Kenyatta National Hospital staff quarters. When some doctors went on strike, the government’s response was to lock them out of their homes, leaving them vulnerable. In response, the Kenya Medical Association formed the Housing SACCO to assist doctors in acquiring homes. This initiative led to the establishment of KMA estates in various locations.

Additionally, in 1997-98, recognizing the need to educate doctors on financial matters, the association initiated a savings and credit society. KMA SACCO was founded in 2000, offering savings and credit services to members. Today, KMA SACCO celebrates its 25th anniversary with an asset base of six billion Kenyan shillings. This initiative has significantly improved the financial status of many doctors. Personally, I have benefited from KMA SACCO and currently I

am on my 10th loan.

In terms of professional development, the Kenya Medical Association oversees the East African Medical Journal, which provides a platform for doctors to publish research findings. This journal, with its centenary celebrated last year, plays a crucial role in advancing the medical profession. Additionally, the association organizes continuous medical education platforms, including webinars for our doctors. Content from these webinars is uploaded on our YouTube page, which became particularly essential during the COVID-19 pandemic.

During the pandemic, KMA partnered with Equity Foundation to manage an 85 million Kenyan shilling project addressing the shortage of Personal Protective Equipment (PPE) and supporting the mental health of frontline health workers. This project included training sessions on PPE usage across all counties, establishment of a call center for psychological support, and collaboration with other professional associations to assist health workers. The association also funded publications documenting these experiences and contributed data to the Ministry of Health meetings, influencing the country’s COVID-19 response.

HCMEA: Is membership in the Kenya

KMA MEMBERS POSING FOR A PHOTO DURING THE ANNUAL SCIENTIFIC CONFERENCE IN MOMBASA, KENYA

KMA’S CEO AND OTHER HEALTHCARE WORKERS

DURING A PUBLIC PARTICIPATION

FORUM ON THE REGULATIONS OF THE SOCIAL HEALTH INSURANCE ACT.

DR. Obondo - CEO, KMA ASSOCIATION FOCUS: Kenya Medical Association (KMA)

Medical Association compulsory for doctors, or is it voluntary? And how do individuals, especially fresh graduates or interns, go about joining?

DR. OBONDO: Membership in the association is voluntary. We’ve attempted to make it mandatory in the past, but it hasn’t been successful due to the existence of another mandatory body, the Kenya Medical Practitioners and Dentists Council, which issues licenses to doctors.

DR. KIGONDU: We, however, engage with medical students from the outset, participating in significant ceremonies like the White Coat Ceremony, Stethoscope Ceremony, and finalist dinner to familiarize them with the association’s role and opportunities.

HCMEA: What are the benefits of becoming a member of the KMA?

DR. KIGONDU: For me, the greatest benefit is networking. As an active member, I’ve built an extensive network of doctors and non-doctors across the medical industry. Today, you can ask me about almost anything in medicine, and I can connect you with the right person.

Beyond networking, the KMA partners with medical suppliers who offer discounts to our members. These partnerships are listed on our website. We also have partnerships with banks that offer preferential treatment to our members.

Professional indemnity insurance, which protects doctors in case of lawsuits, recently became mandatory in Kenya. The KMA negotiates good rates for our members on this insurance, and we’re looking to expand our offerings in this

area in the future.

Ultimately, the KMA serves as a platform for your voice as a doctor to be heard. We provide a powerful platform that doctors can use to make a difference.

HCMEA: What is currently the biggest challenge in terms of diseases, and what is the association doing about it?

DR. KIGONDU: The association remains responsive to emerging health challenges,

THE GOVERNMENT’S EMPHASIS ON PRIMARY HEALTHCARE IS CRUCIAL FOR ACHIEVING UNIVERSAL HEALTH COVERAGE.

prioritizing disease management based on urgency. COVID-19 has been a major focus recently, and we’ve implemented various initiatives to support healthcare workers and communities during the pandemic. Mental health is another area of concern, with issues like alcoholism and substance abuse prevalent even among professionals. Our Physician Wellness Committee, led by Dr. Melanie Mugo, provides support and referrals for doctors facing such challenges.

Maternal health, particularly reducing maternal mortality rates, is also a priority addressed by our Reproductive Health Committee. Additionally, the association comments on and addresses emerging diseases as they arise, ensuring a comprehensive approach to healthcare advocacy and management.

HCMEA: How does the association ensure the right ethical culture among its members?

DR. KIGONDU: Ethics is paramount in the medical profession. We emphasize to medical students the noble nature of their profession and the ethical responsibilities that come with it. As an association, we enforce a code of conduct and monitor members for any breaches, imposing consequences when necessary. Continuous medical education plays a crucial role in

clarifying ethical standards and addressing any ambiguities. Additionally, we remain vigilant against external pressures, such as profit-driven practices by healthcare businesses, that may compromise medical ethics. When such issues arise, we advocate for ethical standards, even if it means confronting businesses or government authorities. Upholding medical ethics ultimately protects the welfare of patients, and we work to ensure that laws enforce professionalism through our advocacy efforts.

HCMEA: How does the KMA work with the government to achieve shared goals in healthcare?

DR. OBONDO: The current government’s focus on healthcare is commendable. We commend them for passing the National Health Insurance Act and transitioning to a social health insurance model.

Their emphasis on primary healthcare is crucial for achieving universal health coverage. We also see positive steps in facility improvement financing and healthcare digitization. Overall, these reforms appear well-designed to support universal health coverage.

The KMA actively contributes to these initiatives. We participate in forums and submit memoranda on health policies. For instance, I participated in Senate meetings on healthcare

KMA

PRESIDENT, DR.KIGONDU AND KENYA’S HEALTH CS, SUSAN NAKHUMICHA

reforms to ensure doctors’ voices were heard on recently implemented laws.

Additionally, our managed health finance committee is currently reviewing the draft regulations for social health insurance to advise the government appropriately. By providing provider perspectives, we help them refine health policies.

HCMEA: Does the association collaborate with other associations internationally, and what benefits does it get from such collaborations?

DR. KIGONDU: Yes, at an international level, KMA actively collaborates with three major medical associations: the Commonwealth Medical Association, the World Medical Association, and National Medical Associations in Africa. Our participation allows us to contribute to global health policy discussions, ensuring that diverse perspectives, particularly from Africa, are considered in shaping international medical policies. Previously, African input was limited, but with KMA’s growth, we now have a voice in international decision-making processes.

We hold significant roles within these associations, such as Vice Presidency in the Commonwealth Medical Association, with ambitions to secure the presidency. Notably, in April 2023, we hosted the World Medical Association council session in Nairobi, further demonstrating our commitment to influencing global medical policy.

Collaboration with international associations also provides us with guidance and support during local challenges. For instance, during the doctor’s strike in 2017, we sought assistance from the World Medical Association, amplifying our advocacy efforts on a national scale.

HCMEA: What would you say would be your biggest achievements during this period that you’ve been at KMA?

DR. OBONDO: Our biggest achievement is our ability to influence policy. Kenya Medical Association actively participates in shaping healthcare policy, such as contributing to the Social Health Insurance Fund. Our input carries weight because it directly impacts the lives of citizens. Having a platform where our voices are heard and respected is invaluable.

DR. KIGONDU: In addition, being recognized at the international level is a significant milestone. KMA’s involvement in global medical associations like the World Medical Association has put us on the map of policymaking. Hosting a council session in Nairobi by the WMA, which I highlighted earlier, underscores our growing influence and contribution to global healthcare initiatives.

HCMEA: Finally, where do you want to see KMA when you leave office?

DR. KIGONDU: I envision KMA maintaining its influential role in shaping policy and upholding professionalism while preserving the social and cultural fabric of our nation. Ensuring the welfare of our members is paramount, as their wellbeing directly impacts the quality of healthcare provided to Kenyans. Our goal is to continue nurturing future leaders through leadership development programs and providing financial education and support to our members.

In the near future, we aim to have a greater presence on social media and other communication platforms, enabling us to disseminate information more efficiently and effectively. By expanding our reach through media and podcasts, we can better educate and engage with the public, ultimately contributing to the improved health of Kenyans.

DR. OBONDO: My top priority is to streamline internal KMA policies and maintain our position as the thought leader in Kenyan health policy. I want by the time I leave office, KMA to be at the forefront of every health policy discussion, ideally driving the agenda. HCMEA

ADVERTISE IN AFRICA & MIDDLE EAST’S NO.1 HEALTH & PHARMA INDUSTRY MAGAZINE & WEBSITE ADVERTISE WITH US TO GROW YOUR BUSINESS . .

WHY ADVERTISE IN HEALTHCARE AFRICA MAGAZINE & WEBSITE?

• Reach the healthcare, pharmaceutical and biotech industry in Africa & Middle East using one publication and website

• The first magazine of its kind in the region that is also available in a digital format, providing our advertisers with a regional and worldwide audience

• The magazine and website are read by key decision makers with direct responsibilities for purchase of new technologies, products and services across Africa, Middle East and globally.

• HealthCareMEA.com is the best read and visited healthcare, pharmaceuticals and biotech news website in Africa and the Middle East.

AI in Healthcare: TRANSFORMING Patient Care, ONE Innovation AT A TIME

The integration of artificial intelligence (AI) into healthcare marks a watershed moment in medical science, heralding a new era of enhanced patient care, groundbreaking research, and streamlined administrative processes. Despite the formidable challenges facing the industry, the continuing improvement of AI offers a sliver of hope as years of dedication to advancing machine learning pave the way for transformative innovations.

UNDERSTANDING AI IN HEALTHCARE

Artificial Intelligence (AI) refers to the development of computer systems that can perform tasks that normally require human intelligence. In healthcare, AI has various applications, from diagnosing diseases to predicting patient outcomes. AI algorithms learn from data and make predictions, a process known as machine learning. A subset of machine learning, deep learning, uses neural networks with multiple layers (hence the term “deep”) to facilitate more complex and accurate predictions.

The global AI in healthcare market size was estimated at USD 22.45 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 36.4% from 2024 to 2030 according to a 2023 report by Grand View Research. The sector has seen significant investment from various sectors. According to a Deloitte state of AI survey conducted in 2019, 19% of healthcare leaders are currently prioritizing investments in AI, and 37% plan to do so over the next three years. Another survey still by Deloitte but which was conducted in 2020 found that AI investments will shift over the next two years to prioritize telemedicine (38%), robotic tasks such as process automation (37%), and delivery of patient care (36%).

Examples of AI technologies already in use in healthcare include medical image analysis,

predictive analytics, and virtual health assistants. On virtual health assistant for example, can now assume the role of a therapist and discuss with someone the way they could curtail their depression. Other application in the healthcare field of emergency care especially in managing life-threatening problems or diseases like cardiac arrests, has demonstrated in unsayable ways how AI can enhance healthcare delivery.

5G AMBULANCES DISRUPT HEALTHCARE DELIVERY

Perhaps the most attention-grabbing AI-related healthcare innovation is the 5G ambulance which was unveiled in a pomp and colorful event for the very first time in Middle East and Africa at the AL Riyadh tech Expo of 2022. The smart 5G-enabled ambulance has the capability to conduct on-scene emergency treatments. Its next generation equipment allows doctors to remotely have access to the ambulance and assess the condition of the patient via smart cameras. The cameras transmit high-definition footage to the doctor with close to zero latency. The vehicle is linked to and shares live measurements of clinical

By STEVE IRERI

AI ALGORITHMS CAN ANALYZE MEDICAL IMAGES, GENOMIC DATA, AND PATHOLOGICAL DATA TO DETECT AND CLASSIFY VARIOUS ABNORMALITIES, LEADING TO MORE ACCURATE DIAGNOSES

data such as the patient’s heart rate as well as their medical records.

Using a Virtual Reality headset and a joystick, the doctor can then remotely guide a paramedic through a series of procedures based on haptic glove technology and attend to the patient conclusively. For extremely complex emergency cases whose medicine is not available in the smart ambulance, smart drones are sent to pharmacy stores to fetch the required medicine in advance.

UHB clinical director Tom Clutton-Block notes that the ambulance can treat someone and discharge them even before it arrives at the hospital, mostly in cases where the disease isn’t grave. “If the emergency condition is not grave, then the patient can be treated virtually. If it is too serious, the treatment can start in the ambulance,” he said in an interview with ZD Net, a leading outlet that focuses on healthcare.

IMPROVING DIAGNOSTICS AND TREATMENT

AI has the potential to enhance diagnostic accuracy and speed, particularly in areas like radiology, pathology, and genomics. AI algorithms can analyze medical images, genomic data, and pathological data to detect and classify various abnormalities, leading to more accurate diagnoses. In the field of personalized medicine, AI is striving to leave an indelible mark. It can now recommend treatment options based on

a patient’s unique genetic makeup and disease profile while it is increasingly being used in drug discovery, helping to identify potential therapeutic candidates more efficiently.

Its impact has been most recognized in Radiology. Traditionally, radiologists interpret medical images produced by X-rays, radioisotopes, ultrasound, and magnetic fields. They work in conjunction with the referring physician and patient to establish a diagnosis and determine an appropriate course of treatment. However, the process is backbreaking, as radiologists must read and interpret hundreds of images a day, increasing the probability of human error. Alongside that, these radiologists come face to face with challenges like poor image quality, lack of support for radiology staff, transcription errors, limited process standardization, and poorly written and/or confusing exam notes that makes their services more prone to errors.

When compared to human radiologists, AI models have shown promising results. For instance, an international team, including researchers from Google Health and Imperial College London, designed and trained a computer model on X-ray images from nearly 29,000 women. The algorithm outperformed six radiologists in reading mammograms. In another study by the University Hospitals Birmingham NHS Foundation Trust, it was found that AI can correctly diagnose disease in 87% of the cases,

INSIDE VIEW OF A 5G AMBULANCE

whereas detection by healthcare professionals yielded an 86% accuracy rate.

These findings suggest that AI models could potentially improve the accuracy of radiology diagnoses, reduce the workload of radiologists, and ultimately lead to better patient outcomes while saving money all through.

STREAMLINING OF ADMINISTRATIVE TASKS

AI-powered tools are streamlining administrative tasks in healthcare, reducing paperwork, and improving operational efficiency. Virtual health assistants and chatbots, powered by AI, provide round-the-clock support to patients. They can answer queries, monitor health metrics, and even assist with medication management. This allows healthcare professionals to spend more time on patient care and less time on administrative duties.

AI also has the potential to improve patient outcomes through predictive analytics. By analyzing large amounts of patient data, AI can predict the likelihood of certain diseases and suggest preventative measures. Take the example of a patient with a family history of a rare genetic disorder. AI algorithms can analyze their genetic markers, lifestyle factors, and environmental influences to predict the risk of developing the condition. Early intervention can then be recommended to mitigate potential harm.

LOWERING HEALTHCARE COSTS

Beyond improving quality of care, AI also has the potential to lower finance costs. A report from the National Bureau of Economic Research in 2023 suggested that greater adoption of AI could also lead to 5–10% savings in U.S. healthcare spending, equating to anywhere from US$200 billion to US$360 billion annually.

The adoption rates of AI technologies in healthcare settings vary, however. According to statista.com, a 2021 survey reported that 45% of respondents were currently using AI technology or had plans to use it before the end of 2021 for healthcare data integration. Furthermore, 36% of organizations had implemented or were planning to implement natural language processing hinting at a growing interest in leveraging AI for tasks like clinical documentation, patient engagement, and decision support.

ETHICAL STANDARDS

The use of AI in healthcare raises several ethical implications, including privacy concerns,

algorithmic bias, and patient consent. It’s crucial to ensure that AI technologies respect patient privacy, provide unbiased results, and are used with informed patient consent.

Several initiatives and organizations are working to establish ethical standards and guidelines for AI in healthcare. One of them is the World Health Organization (WHO) which has released new guidance on the ethics and governance of large multi-modal models (LMMs), a type of fast-growing generative AI technology with applications across healthcare. The guidance outlines over 40 recommendations for consideration by governments, technology companies, and healthcare providers to ensure the appropriate use of LMMs to promote and protect the health of populations.

The WHO guidance explains that there is a dire need for transparent information and policies to manage the design, development, and use of LMMs to achieve better health outcomes and overcome persisting health inequities. It also highlights the potential benefits and risks of LMMs, such as their ability to improve diagnosis and clinical care, but also the risk of producing false, inaccurate, biased, or incomplete statements, which could lead to harm if such information in making health decisions. HCMEA THE

Healing the Rift: Addressing Brain Drain In Africa’s Healthcare Sector

By Vincent Moranga

Healthcare systems in Africa have suffered from neglect and underfunding, leading to severe challenges across the six World Health Organization (WHO) pillars of healthcare delivery. These pillars include service delivery, healthcare workforce, information systems, medicines and technologies, financing, and governance. Moreover, the issue is exacerbated by the phenomenon of brain drain, as skilled healthcare personnel often seek better opportunities abroad, further straining an already fragile healthcare workforce.

The debate over the ‘brain drain’ of health practitioners from developing to developed countries has been ongoing for decades. While brain drain poses significant challenges to Africa’s overall development, its impact on the healthcare sector is particularly severe. In fact, the critical shortage of healthcare professionals poses the most significant obstacle to Africa’s endeavours in combating AIDS and advancing other health initiatives. Various factors contribute to brain drain,

categorized as either push or pull forces.

Push factors are often defined as circumstances that compel an individual to leave their nation of origin, such as chronic young unemployment, poor quality of education or work, and unstable political environments. On the other hand, pull factors includes high living standards, easier access to healthcare, more favourable job opportunities, and cultural appeal that entice people to go abroad. Doctors and other professionals are driven to look for possibilities abroad by factors such as corruption and poor governance.

LOST IN THE NUMBERS

The extent of Africa’s brain drain in terms of numbers remains unclear, largely due to challenges in data collection exacerbated by porous national borders in African nations. Despite this, the African Union (AU) has been actively working to quantify the departure of highly qualified professionals, which has had detrimental effects on the healthcare workforce. With

between 10 to 12 million young Africans entering the labour force annually in a job market that can only support about 3 million jobs per year, the AU estimates that 70,000 qualified workers leave Africa annually. This trend is partly driven by the limited economic prospects available within the continent, pushing many to seek better opportunities abroad, particularly in Europe and America.

Moreover, evidence from the Organization for Economic Cooperation and Development (OECD) suggests that there is a significant increase in African migration to OECD nations, with projections indicating a potential rise to 34 million migrants by 2050. Among the sub-Saharan African diaspora, approximately 50.0% resided in France, the UK, and the US in 2013. This mass exodus of skilled professionals, including doctors and nurses, has disproportionately impacted several African nations, such as Nigeria, Ghana, and Zimbabwe, exacerbating the strain on their healthcare systems.

For instance, in Nigeria, the healthcare workforce is severely strained, with a stark ratio of one doctor for every 5,000 patients, compared to the much lower ratio in wealthy countries. The National Association of Nigeria Nurses and Midwives has reported similarly dire statistics, with an alarming shortage of nurses and midwives. This shortage can also be attributed to

the departure of over 75,000 nurses since 2017, reflecting the significant impact of brain drain on Nigeria’s healthcare sector.

Similarly, Ghana and Zimbabwe have also experienced substantial losses in their healthcare workforces due to migration. In 2022 alone, over 1,200 Ghanaian nurses migrated to the UK, while more than 4,000 nurses departed Ghana. Zimbabwean government data also indicate a similar trend, with more than 4,000 health workers, including 2,600 nurses leaving the country to seek better opportunities overseas in 2021 and 2022. These departures have left these countries grappling with critical shortages in their healthcare workforce, hindering their ability to achieve universal health coverage.

A DOUBLE LOSS FOR AFRICAN HEALTHCARE

Africa’s brain drain erodes the quality of local patient care and destabilizes the already vulnerable healthcare system. As a result, some local healthcare providers find themselves unable to provide adequate care, leading to the rise of outbound medical tourism. For example, Nigeria’s poor healthcare facilities have led to medical tourism abroad, which costs the Nigerian economy approximately US$1.2 billion each year.

This economic impact is not restricted to Nigeria; other nations, such as Kenya, lose

34 Million IN NUMBERS

PROJECTED NUMBER OF AFRICAN MIGRANTS TO OECD NATIONS BY 2050

Source: WHO

$517,931 for each migrant doctor and $338,868 for each migrant nurse. According to Eatona, Baingana, and colleagues’ research paper, “Addressing the Adverse Effects of Global Health Worker Migration,” this financial computation is primarily based on the costs associated with their education and the eventual loss of that investment over a 35-year professional career.

Notably, this assessment fails to consider the broader economic effects of a lack of health promotion, preventative measures, treatment, and rehabilitation services, as well as the impact of a lack of supervisors, mentors, and role models. Furthermore, it ignores the decreased effectiveness of the referral system, reduced employment prospects for support workers, and decreased tax revenue.

As African nations lose medical and professional expertise to high-income countries such as the United States, Canada, Australia, and the United Kingdom, these destinations profit by strengthening their healthcare systems. This becomes important as they face an acute shortage of locally qualified professionals, which has resulted in an increased reliance on personnel trained abroad.

Currently, the UK National Health Service (NHS) has 356,506 registered doctors, with 146,984 (36%) receiving their training abroad.

Of these, 110,929 (75.4%) were trained outside of the European Economic Area (EEA). According to General Medical Council (GMC) data released in November 2022, there are already 78,823 doctors on the medical registry who were trained in the world’s 57 poorest countries. This places additional strain on African countries’ already deteriorating healthcare systems.

DOCTORS OF TWO WORLDS

Brain drain has profoundly impacted Africa’s healthcare sector, with many skilled practitioners seeking opportunities outside the continent. This trend is evident in the substantial differences in physician-to-population ratios among African nations, as highlighted by data from the World Health Organization’s Global Health Workforce Statistics.

For instance, in 2017, Burundi had a mere 0.1 physicians per 1,000 population, contrasting starkly with Zambia’s 1.2. Similarly, Zimbabwe recorded 0.2 physicians per 1,000 people in 2016, while Guinea had only 0.1, Eswatini boasted 0.3, and South Africa reported 0.9 in 2018.

During the same periods, European countries, the United States, and other industrialized nations maintained significantly higher physician-topopulation ratios, typically between 3 and 4 physicians per 1,000 people.

The United Kingdom has notably gained from the approximately 6,770 Nigerian nationals who have contributed to its National Health Service. Conversely, Nigeria, the primary provider of these professionals, faces a severe shortage, with only one doctor for every 5,000 people which is far below the World Health Organization’s recommended ratio of one doctor per 600 individuals. Consequently, a staggering 57% of Africans lack access to high-quality healthcare services.

SHRINKING WORKFORCE, GROWING CRISIS

Regardless of the push and pull considerations, the migration of healthcare workers from developing to developed countries has harmed healthcare delivery in developing countries. The World Health Organization (WHO) predicts that more than 4 million healthcare workers will be required globally to address the practitioner shortage, including at least 2.4 million doctors, nurses, and midwives, with Sub-Saharan Africa facing a one million healthcare worker shortage.

Despite the variations in contributing factors to African brain drain, certain commonalities exist. In Sierra Leone, for example, poor working conditions, limited training opportunities, inadequate career prospects, and security concerns are major migration catalysts. Similarly, Nigeria experiences physician loss due to low pay and insufficient financial investment in healthcare, perpetuating the problem of understaffing, a recurring issue across many African nations.

Nigeria and Sierra Leone are not the sole countries grappling with brain drain; the introduction of South Africa’s National Health Insurance (NHI) system could further exacerbate the emigration of medical professionals from the country’s healthcare sector. This is primarily due to uncertainties regarding compensation, job security, and the evolving nature of the medical profession. The South African Medical Association (SAMA), which represents 17,000 doctors, anticipates that widespread distrust in the government may prompt up to 38% of its members to leave South Africa if the NHI is implemented.

BRIDGING THE GAP

In this era of unstoppable globalization, talent mobility emerges as a promising avenue for African nations. Many countries across the continent view talent mobility as an opportunity

for knowledge exchange, leveraging diaspora networks, accessing remittances, fostering brain gain, and enhancing global competitiveness. For instance, Morocco is proactively involving its diaspora through initiatives such as the International Forum of Moroccan Competencies Abroad, aimed at bolstering national research and technology endeavours. Similarly, Cameroonian pharmacists living in Belgium have partnered with the University of Douala to deliver foundational pharmacy training programs.

Telemedicine, digital health records, and mobile health initiatives are other promising avenues for enhancing healthcare delivery in Africa and increasing its attractiveness to local professionals. Notably, the adoption of the ECHO Clinics model, which has successfully been implemented elsewhere, is now being replicated in African nations such as South Africa, Malawi, and Kenya, democratizing medical knowledge and promoting collaboration between experts and patients.

Several African countries have also been promoting “circular mobility,” by allowing immigrants to work and specialize in their fields for a few years before returning to their native countries. For instance, in 2018, Kenya signed a bilateral agreement with Cuba, which involved bringing 100 Cuban doctors to address gaps in county hospitals while 50 Kenyan doctors were

Source: Duvivier et al

sent to Cuba for specialized training in family medicine.

Task shifting has also been recognized globally as a strategy for improving healthcare access. It involves delegating tasks from experienced professionals to less specialized healthcare employees. The Africa CDC’s recent initiative to recruit 2 million community health professionals is seen as a viable approach to reducing brain drain, as it serves to enhance epidemic prevention, detection, and response, as well as providing care for HIV, TB, and malaria to Africa’s rural and underserved populations.

STEMMING THE TIDE

Despite African countries seeming powerless to halt the brain drain, concerted efforts are being made by African governments and partners to develop various policy frameworks, programs, and strategies aimed at retaining, recalling, and replacing lost talent. For instance, the African Union (AU) has developed The Revised Migration Policy Framework for Africa and Plan of Action (2018-2027), which is crucial in aiding African nations to counter the emigration of skilled individuals to OECD countries, thereby creating significant opportunities within the continent.

To mitigate the brain drain phenomenon, especially among health professionals, the report suggests promoting the NEPAD strategy for retaining Africa’s human capacities. This involves implementing gender-responsive economic development programs to offer employment, professional growth, and educational avenues to qualified nationals within their domestic borders.

The report also proposes countering the effects of brain drain by encouraging nationals living abroad to contribute to the development of their countries of origin. This could be achieved through various means, including financial and human capital transfers, fostering short and long-term return migration, and facilitating the transfer of skills, knowledge, and technology. Initiatives like the IOM MIDA Programme and efforts from organizations such as the ILO and WHO are cited as relevant in this context.

Additionally, the report suggests establishing policies to replace qualified individuals who have left their home countries and implementing retention strategies to retain skilled professionals. Several nations, such as Kenya and South Africa, have previously implemented this strategy to retain more students seeking a higher-quality education overseas.

Furthermore, the report also emphasizes the importance of maximizing the contribution of skilled professionals to the continent by facilitating regional and continental mobility. Sudan, for example, has inked bilateral agreements about health worker migration with Saudi Arabia and Ireland and aspires to promote the Sudanese diasporas’ engagement in health system improvement and development through skills and knowledge transfer and training of their local counterparts.

In addition to these efforts, it is also crucial to address workplace discrimination against women. High-skilled female migrants are currently the fastest-growing group of migrants in Europe and Central Asia. Providing more opportunities for women would naturally decrease the departure of highly skilled women, helping countries mitigate the brain drain. Similar programs are being implemented in Somalia and Tanzania to ensure the full realization and longterm sustainability of community-based health initiatives, as stated by the World Bank.

FROM EXODUS TO RESILIENCE

Given the increasing challenges posed by brain drain in Africa’s healthcare industry, it is crucial to emphasize the importance of retaining and nurturing healthcare expertise on the continent. The emigration of experienced healthcare

workers not only depletes the workforce but also threatens the foundation of the healthcare infrastructure. Retaining these skills is critical because they form the backbone of the healthcare system, providing essential services and contributing to community well-being.

In conclusion, the critical examination of the brain drain in Africa’s healthcare sector demonstrates the crucial need for quick attention and joint action. The causes, repercussions, and facts presented clearly show the gravity of the situation. The importance of healthcare professionals in Africa cannot be overstated, considering the presence of difficulties such as poor infrastructure, emerging epidemics, lifestyle diseases, and political instability that necessitate prompt response.

Despite the massive hurdles created by healthcare worker migration in Africa, there is a ray of optimism coming from government initiatives, international collaborations, and success stories from diverse nations. These initiatives have proven helpful in combating brain drain and provide a viable road map to sustainable change. Looking ahead, it is critical to recognize technology’s essential role and advocate for the implementation of long-term policies to promote sustainable healthcare workforce development.

HCMEA

I left Nigeria because I wanted to earn more money, learn new things and to practise in a better environment

A Nigerian doctor currently practicing in the United States told Africa Renewal.

QATAR : Middle East and Africa’s leader in healthcare delivery

By Vincent Moranga

In October 2008, Qatar unveiled its ambitious Vision 2030 (QNV 2030), a comprehensive blueprint aimed at steering the nation toward a prosperous future. Central to this vision was the recognition of human development as a fundamental pillar. The Qatari leadership underscored the crucial link between a healthy populace and sustainable progress. “A healthy population served by a world-class, well managed healthcare system available to all is essential to Qatar’s development,” states the QNV blueprint.

Consequently, Qatar crafted a meticulous long-term strategy to realize the health objectives outlined in QNV 2030. This strategy revolves around seven key goals:

1. Establishment of a comprehensive, worldclass healthcare system accessible to all

citizens.

2. Integration of healthcare services to ensure delivery of high-quality care.

3. Emphasis on preventive healthcare tailored to the diverse needs of individuals across all demographics.

4. Development of a proficient national healthcare workforce capable of delivering superior services.

5. Formulation and enforcement of a national health policy to set and uphold standards.

6. Provision of effective and affordable healthcare services, with a focus on shared responsibility in cost-sharing.

7. Investment in cutting-edge research aimed at enhancing the efficacy and quality of healthcare delivery.

Qatar’s healthcare system has made

remarkable strides towards these goals, evidenced by the significant increase in life expectancy, currently the highest in the region at 80.3 years. This stands in stark contrast to the approximately 76 years recorded back in 2011, when the first national health strategy was launched. Despite this progress, Qatar remains resolute in its pursuit of further advancements, setting its sights on elevating life expectancy to 82.6 years by 2030.

This article delves into Qatar’s ongoing efforts to bolster its healthcare infrastructure and the formidable challenges it faces in realizing its 2030 national vision of a healthcare system that “meets the needs of existing and future generations and provide for an increasingly healthy and lengthy life for all citizens.”

A WORLD-CLASS HEALTH CARE SYSTEM ACCESSIBLE TO ALL

Qatar has been deliberate in its efforts to provide its all its citizens with world-class care. The country has invested heavily both in infrastructure and standards to ensure that its citizens receive the highest quality of care possible. Since the start of the implementation of the national health strategy, Qatar has been able to raise the number of hospitals to 16 from six in 2011. A prominent addition is the Aisha bint Hamad Al Attiyah Hospital, inaugurated in November 2022. Boasting 300 treatment rooms in its main building, it stands as the second largest public sector hospital following Hamad General Hospital, in both size and capacity.

Aisha bint Hamad Al Attiyah Hospital is affiliated to the Hamad Medical Corporation (HMC), which is the primary provider of secondary and tertiary healthcare in Qatar, oversees numerous hospitals, emergency services, specialized and ambulatory care centers, as well as national ambulance and home healthcare services.

State-funded primary healthcare has seen substantial investments in facilities and is managed by the Primary Health Care Corporation (PHCC). According to the Qatar National Agency, facilities managed by the PHCC, along with those operated under an agreement with the Ministry of Public Health by the Qatar Red Crescent, increased to 33 centers in 2023 from 24 in 2011.

Noteworthy additions include the Al Mashaf Health Center with capacity to attend to 35,000 to 50,000 patients, and the Al Khor Health Center with a capacity of 50,000.

To ensure public health practices in the

State of Qatar are implemented in accordance with the highest international standards, Qatar pursued and obtained international accreditation for public health services at the national level from the American Board of Accreditation of Public Health Services, for a period of five years, becoming the first country in the world to obtain this international accreditation after the United States of America.

In addition, five of Hamad Medical Corporation (HMC) facilities and services won the Excellence Award for Patient-Centered Care in March 2022, these are the Communicable Disease Center; the Home Health Care Service; the Private Nursing Service; the Ambulatory Care Center and the Enaya Specialized Care Center.

Furthermore, five hospitals in Qatar ranked among the top 250 academic medical centers

THE STATE OF HEALTH IN QATAR

Source: Duvivier et al

in the world and two hospitals among the top 100 centers. This accreditation confirms Qatar healthcare sector’s commitment to combining patient care, medical research and education to achieve the best outcomes and experiences for patients.

Qatar’s efforts to building a worldclass healthcare system have not gone unnoticed. In 2022, World Health Organization granted the “Healthy City” status to all eight municipalities, making Qatar the first country in the world to achieve this status for all its municipalities. According to WHO, a healthy city is defined as one that continually creates and improves the physical and social environment and expands community resources for enabling the mutual support among population groups for living. WHO has also given similar awards to the Education City of Qatar Foundation for Education, Science and Qatar University.

A SKILLED NATIONAL WORKFORCE Qatar’s healthcare system faces

significant challenges stemming from its rapidly growing and fluctuating population, largely driven by its expatriate-centric economy. In September 2017, the population stood at 2.624 million, with Qataris comprising only about 12% and expatriates forming the majority at 88%. The influx of expatriates, particularly during major events like the FIFA 2020 World Cup hosted by Qatar, exacerbates these demographic shifts.

A report from Reuters in October 2022 highlighted a substantial population surge, reaching 2.94 million, marking a staggering 13.2% increase over the previous year. This surge was primarily attributed to the recruitment of overseas workers as Qatar geared up to host the soccer World Cup, anticipating an unprecedented influx of fans.

Qatar recognizes the strain that such rapid population growth places on its healthcare infrastructure, leading to a decline in the doctor-to-population ratio. To mitigate this, the country heavily relies on expatriate healthcare

professionals, who currently make up 69% of doctors and 91% of nurses. Qatar offers competitive salaries and benefits to attract and retain these professionals, with average monthly salaries for doctors ranging from US$5000 to US$10,000, and specialists earning as much as US$47,000 per month— often more than five times what many expatriates earn in their home countries, rendering Qatar an attractive destination.

At present, Qatar boasts a doctorto-population ratio of 2.5 per 1000 individuals, significantly surpassing the WHO’s recommended ratio of 1:1000. Additionally, the country has 58.8 nurses or midwives, 5.4 dentists, and 7.6 pharmacists per 10,000 people. To bolster its physician numbers, Qatar University has partnered with Weill Cornell Qatar, offering programs aimed at developing the Qatari physician workforce and reducing reliance on expatriates.

However, Qatar acknowledges the continued essential role that expatriates

will play, not only in healthcare but also across various sectors of the economy. A section of the QNV report underscores this, stating, “For the foreseeable future, Qatar will not have a sufficient number of citizens to manage the complex systems, infrastructure, and other requirements of a rapidly growing, diversifying, and technologically sophisticated economy.”

AN INTEGRATED SYSTEM OF HEALTH CARE

Qatar has embarked on an ambitious mission outlined in its QNV2030 to overhaul its healthcare system, aiming to elevate the health standards of its population. Central to this vision is the establishment of an integrated healthcare framework managed to meet global benchmarks. Key initiatives include fostering enhanced information exchange among hospitals and ensuring patients are directed to secondary and tertiary healthcare facilities only upon referral from primary healthcare centers.

In pursuit of this objective, Qatar has implemented a unified clinical information system across HMC hospitals and PHCC health centers, with plans underway to extend this system to

encompass all public providers. This concerted effort seeks to foster cohesion and synergy within the healthcare ecosystem, ultimately enhancing efficiency, improving the quality of care, and elevating the patient experience.

Additionally, Qatar took significant strides in 2022 with the inception of the Qatar Health Information Exchange Platform. This pivotal platform aims to streamline the integration of diverse electronic systems and bolster data collection processes, laying a foundation for more seamless healthcare delivery.

Furthermore, Qatar unveiled the Qatar Cancer Information Center in 2022, signaling a landmark commitment to cancer care. This center serves as a hub for comprehensive cancer information governance, facilitating communication among relevant stakeholders to disseminate reliable, up-to-date information about cancer. Beyond information dissemination, the center plays a pivotal role in shaping cancerrelated policies and strategies, leveraging robust scientific data to foster knowledge exchange and resource enhancement through collaborative networking efforts.

RATIO OF DOCTORS PER 1000 INDIVIDUALS IN QATAR 2.5

SIDRA MEDICAL AND RESEARCH CENTER, A 400-BED WOMEN’S AND CHILDREN’S HOSPITAL, MEDICAL EDUCATION AND BIOMEDICAL RESEARCH CENTER IN DOHA, QATAR.

5 hospitals in Qatar have been ranked among the top 250 academic medical centers in the world

NEW LAW A BOON FOR HEALTH INSURANCE

In Qatar, ensuring healthcare accessibility extends beyond mere infrastructure, with a robust mandate requiring all Qatari citizens and residents to possess health insurance. Under this law, the government assumes responsibility for individuals’ insurance premiums, granting them access to free or subsidized primary healthcare services at public hospitals, health centers, and clinics.

However, this safety net doesn’t extend to the majority of Qatar’s population—foreign nationals, who make up 88% of the total population. For them, Qatar’s compulsory health insurance law, enacted in May 2022, mandates holding medical insurance throughout their stay in the country, unless they qualify for an exemption.

American credit rating agency S&P forecasts that this legislation could yield an additional QAR1bn to QAR1.5bn ($275m) in gross written premiums in Qatar over the coming years. Fitch Solutions, a market research and analytics firm, echoes this sentiment, projecting growth until 2028 in line with Qatar Vision 2030.

Furthermore, it’s commonplace for Qataris to complement their public health insurance

with private coverage, affording them access to superior and expedited medical care at private health centers. Many employers also offer private health insurance as part of their employment packages.

PRIVATE SECTOR EXPANDS UNDER QNV2030

Currently, the Qatari Government shoulders 89.5% of national health expenditures. Embracing its Vision 2030, Qatar is committed to expanding private sector involvement in healthcare provision, aiming to increase the share of healthcare beds provided by private entities from 20% to 25% by 2030.

Buoyed by increased government backing, the private healthcare sector witnessed notable expansion in 2022. The sector saw a surge in facilities, including 10 hospitals, 19 ambulatory surgery centers, 390 general and specialized health centers (including dental facilities), and 31 diagnostic centers, encompassing medical laboratories, diagnostic radiology centers, and dental laboratories.

According to a report by BMI, a branch of Fitch Solutions, this trend of heightened private

THE STATE OF HEALTH IN QATAR

Source: Duvivier et al

sector participation is expected to endure in the foreseeable future. The report forecasts a compound annual growth rate of 5.2% in Qatar’s healthcare expenditure over the next five years, reaching nearly $11 billion (QAR40 billion) by 2028.

“The government’s ongoing drive towards privatization will likely result in private spending outpacing public expenditure. We anticipate this momentum to persist as the government gradually shifts the burden of healthcare sector expenses away from the state in the medium term,” the report explained.

CHRONIC ILLNESSES, INJURIES AND CONGENITAL DISEASES HAMPER PROGRESS

Qatar’s strides towards providing world-class healthcare are commendable, but entrenched lifestyle habits pose formidable hurdles to the nation’s vision for a healthy future. The second national health strategy (NHS II) paints a stark picture: 70.1% of the adult Qatari population grapple with overweight or obesity, with 28.7% falling into the overweight category and a staggering 41.4% classified as obese.

Moreover, smoking remains a prevalent issue, with 31.9% of men and 1.2% of women partaking in the habit. Among youth aged 13-15, self-reported tobacco use stands at 15.7%, with boys accounting for 22.8% and girls 8.8%, as per the Global Youth Tobacco Survey. The dental health of Qatar’s population, especially children, is also a concern, with the Ministry of Public Health estimating that around 88% of Qatari and 61% of non-Qatari six-year-olds exhibit signs of dental decay.

These lifestyle-related challenges contribute to alarming

health outcomes. Chronic conditions, including cardiovascular diseases (24%), cancer (18%), and diabetes (7%), are responsible for 69% of mortalities, according to the Ministry of Public Health (MOPH). Notably, Qataris’ diabetes rate stands at 16.4%, well surpassing the global average of 6.4%.

In response, Qatar has prioritized health prevention. NHS II underscores this commitment, stating, “We aim to invest in the promotion of health through healthy behaviors and lifestyle, screening, early detection, and disease prevention.”

To tackle these pressing issues, Qatar has set ambitious targets. It aims to reduce the obesity prevalence by 3 percentage points for all residents and Qataris, from 32% to 29% and 40% to 37%, respectively. Similarly, the goal is to decrease the smoking rate among adult men by 3 percentage points from the current 32%.

Addressing consanguineous marriages, which often lead to genetic disorders, Qatar has launched educational campaigns and seeks to reduce such unions among first cousins from 34% to 27%.

Additionally, Qatar is implementing workplace health programs to reduce injuries lasting more than three days to 3,000 or less per 100,000 workers. Furthermore, the country aims to ensure at least 50% of individuals in target groups are covered by screening programs. Initiatives like the ‘Screen for Life’ breast and bowel screening program, initiated in December 2016, aim to raise awareness and promote early detection of cancer across Qatar. HCMEA

Evolution of HIV Management:

A Comprehensive Review of Recent Progress and Innovations DISEASE FOCUS

By STEVE IRERI

Since the identification of the first known case in 1959, HIV has cast a long shadow. A report by ReliefWeb estimates that over 85.6 million people have been infected worldwide, with 40.4 million succumbing to AIDS-related illnesses. Despite this immense human cost, the field of HIV research has witnessed remarkable progress, particularly since the 1980s.

However, significant challenges remain. Stigma and misconceptions surrounding HIV persist, hindering preventative measures and access to care. Fortunately, the pace of scientific discovery is accelerating. Technological advancements in pharmacology, genetic engineering, genomics, and artificial intelligence are revolutionizing our understanding of health and disease. These breakthroughs hold immense promise for improving HIV management and potentially eradicating the virus.

In this article, the Healthcare Middle East and Africa Magazine examines the progress made in the HIV field.

PROGRESS IN ANTI-HIV MEDICATION

In 1987, the first anti-HIV medication, azidothymidine (AZT), emerged, originally developed as a cancer treatment in the 1960s. AZT significantly reduced mortality and opportunistic infections in AIDS patients by inhibiting HIV’s reverse transcriptase enzyme, falling under the category of nucleoside reverse transcriptase inhibitors (NRTIs). However, AZT’s effectiveness was limited due to the rapid mutation of viruses.

After AZT’s discovery, more NRTIs were developed, alongside the approval of the first protease inhibitor (PI) by the FDA in 1995. PIs, like NRTIs, reduce viral loads but target the protease enzyme to disrupt virus maturation. Other advancements included the approval of the first nonnucleoside reverse transcriptase inhibitor (NNRTI) in 1996, the first entry inhibitor in 2003, and the first integrase strand transfer inhibitor (INSTI) in 2008.

A significant breakthrough occurred in the late 1990s with combining therapies, which are highly active antiretroviral therapy (HAART) or combination antiretroviral therapy

(cART). HAART extended the life expectancy of AIDS patients, although adherence was challenging due to the requirement for multiple daily pills. In response, a combination pill containing two anti-HIV medications was approved in 1997, simplifying treatment and improving adherence rates.

LONG-ACTING ANTIRETROVIRAL THERAPY

In recent years, long-acting antiretroviral therapy (LA-ART) has brought significant advancements to HIV management. In 2021, the FDA approved the first combination of long-acting injectable ART (LAI-ART), cabotegravir and rilpivirine.

Cabotegravir, an integrase strand transfer inhibitor (INSTI), boasts high resistance barriers and potent antiviral properties, while rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), effectively targets NNRTI-resistant HIV. Together, these drugs offer potent and long-lasting effects, owing to their strong antiretroviral activity and extended halflife when formulated into nanosized drug crystals suitable for intramuscular depot injection.

LAI-ART, like cabotegravir and rilpivirine, provides convenience by significantly reducing the daily pill burden of traditional ART to only six or twelve intramuscular injections per year. Moreover, these injections are administered under medical supervision, addressing adherence challenges associated with oral medication. Additionally, LAI-ART helps mitigate the social stigma linked with daily oral anti-HIV treatments, offering emotional benefits to individuals living with HIV.

Innovations in LA-ART extend beyond injectables. Researchers are exploring long-lasting implants and antibody-based strategies. Islatravir, a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI), is being developed as an implant with a dosing interval of one year or longer.

In late 2022, Lenacapavir, also known as Sunlenca, secured FDA approval as the second injectable HIV medication. It represents a breakthrough as a capsid inhibitor, belonging to a new class of drugs that target the protective shell of the virus, hindering its ability to replicate. Lenacapavir offers the potential to reduce doctor visits to twice a year. However, its approval is limited to individuals whose virus has developed resistance to other medications.

Despite its benefits, LA-ART has limitations. Current LAART formulations are administered at fixed standard doses, neglecting patient-specific factors like weight and host characteristics influencing drug disposition. Additionally, many patients experience significant pain and discomfort at the injection site, prompting ongoing efforts to mitigate these issues through extended injection intervals or alternative delivery methods like microneedle patches.

NEW APPROACHES UNDER DEVELOPMENT

Meanwhile, new approaches are being developed to cope with HIV:

HIV VACCINES

Researchers are currently working on developing a therapeutic HIV vaccine, which is designed to treat the condition rather than prevent it. Individuals who are already living with HIV would receive this vaccine to help bolster their immune system’s ability to combat the virus. The ultimate goal is for the vaccine to halt the progression of HIV to AIDS without the necessity for antiretroviral therapy (ART).

The development of an effective HIV vaccine has proven challenging thus far. Traditional vaccines typically use a weakened or inactivated form of a virus to stimulate the body’s production of antibodies. However, this approach has not been successful with HIV due to the difficulty in weakening the virus, and using a live form of the virus is too risky.

Nevertheless, progress is being made in a different type of vaccine approach. The HTI vaccine is designed to instruct T cells, a type of immune cell, to target a specific component of the virus crucial for its replication. In a small-scale study involving 45 patients, 40 percent of those who received the vaccine were able to delay the initiation of ART for up to 22 weeks.

Researchers are now investigating the potential of combining the HTI vaccine with the experimental drug vesatolimod. This drug has the potential to enhance the body’s immune response to the vaccine, potentially increasing its effectiveness for a broader range of individuals or prolonging its effects. This ongoing research represents a promising avenue in the quest for an effective therapeutic HIV vaccine.

GENE EDITING

Gene editing presents a promising avenue for HIV treatment.

This technology involves altering an organism’s DNA. While it has primarily been studied in genetic diseases like cystic fibrosis, hemophilia, and sickle cell disease, researchers are now exploring its potential in combating HIV.

individuals with HIV to lead relatively normal lives. However, despite the effectiveness of these treatments, some HIV remains dormant inside cells, a state known as “latency.” If ART is discontinued, the dormant HIV can awaken, leading to replication and the development of acquired immunodeficiency syndrome (AIDS). In the pursuit of a cure, researchers have been striving to awaken latent HIV and target it for elimination.

A recent clinical trial, spearheaded by Cynthia Gay, MD, MPH, and David Margolis, MD, along with other clinicians and researchers at the UNC School of Medicine, investigated a combination therapy involving the drug vorinostat and immunotherapy to coax HIV-infected cells out of latency and combat them.

Immunotherapy was administered by a team led by Catherine Bollard, MD, at George Washington University. This involved extracting white blood cells from study participants, enhancing their ability to target HIV-infected cells in the laboratory, and then reintroducing them at UNC.

The findings revealed a modest reduction in the latent HIV reservoir. While this represents progress, it underscores the need for further research and refinement in this area.

The ultimate goal is for the vaccine to halt the progression of HIV to AIDS without the necessity for antiretroviral therapy (ART).

Preliminary experiments on animals have shown that a form of gene editing known as CRISPR could potentially render a virus similar to HIV, called simian immunodeficiency virus (SIV), ineffective. SIV is found in animals such as monkeys.

Human clinical trials utilizing CRISPR technology began in late 2021. In these trials, researchers aim to use CRISPR to remove the HIV that integrates into the DNA of cells, making it challenging to treat.

The overarching goal is to develop a treatment that differs from ART, which necessitates lifelong adherence. Instead, the hope is that a single CRISPR treatment could potentially cure HIV, offering a transformative shift in HIV management and treatment.

IS A CURE ON THE HORIZON?

Antiretroviral therapies (ART) have been instrumental in halting HIV replication, enabling

David Margolis, MD, director of the HIV Cure Center and senior author of the paper, acknowledged the importance of the approach but emphasized that significant reductions in the HIV reservoir were not achieved. He emphasized the necessity for continued efforts to develop more effective strategies to flush out latent virus and eradicate it, highlighting the ongoing commitment to advancing HIV cure research.

FINAL THOUGHTS

Despite the absence of a cure for HIV, individuals with access to anti-HIV therapy now enjoy a life expectancy close to that of the general population. The introduction of long-acting antiretroviral therapy (LA-ART) holds promise in further enhancing the quality of life for those living with HIV, while also reducing the burden of adherence associated with traditional ART.

Significantly, advancements in anti-HIV therapy throughout recent decades have transformed what was once a fatal illness into a manageable chronic condition. HCMEA

HMD introduces Dispojekt syringes to reduce needle stick injuries

INDIA — Hindustan Syringes and Medical Devices (HMD), a leading Indian medical device manufacturer, has launched the Dispojekt range of syringes equipped with safety needles and Sharps Injury Prevention shields.

These innovative syringes aim to reduce Needle Stick Injuries (NSIs) among healthcare workers, cutting costs

related to infection control and disposal.

Manufactured domestically with advanced technology, they position India as a global leader in sharp injury prevention syringes.

Rajiv Nath, Managing Director of HMD, stressed their commitment to healthcare excellence and India’s role in global medical equipment production.

Clinical trials support the safety and efficacy of Dispojekt syringes, endorsed by organizations like the EU, US, and WHO.

HMD plans to capture a significant market share and invest in expanding production to combat NSIs and bloodborne diseases globally.

These affordable syringes cater to underdeveloped regions, reflecting HMD’s dedication to accessible healthcare solutions.

Siemens launches interactive anatomy app

GERMANY - Siemens Healthineers has launched a groundbreaking app, Cinematic Reality, compatible with Apple Vision Pro.

This innovative tool allows users, including surgeons, medical students, and patients, to interact with immersive holograms of the human body derived from medical scans.

The app facilitates surgery planning, medical education, and patient understanding of treatments.

Leveraging Apple Silicon and Metal, it promises future development potential. Cinematic Reality enhances clinical communication, aids preoperative planning, and fosters multidisciplinary collaboration among healthcare professionals.

Users can seamlessly navigate clinical photos, zoom in on details, and rotate anatomical simulations.

Christian Zapf, Director of Digital and Automation at Siemens Healthineers,

highlighted the app’s photorealistic simulations and its potential for clinical and educational applications.

Sebastian Krueger, principal developer of Cinematic Reality, emphasized the app’s adaptation to the Apple Vision Pro’s M2 processor, delivering realistic lighting and reflections.

THE APP FACILITATES SURGERY PLANNING, MEDICAL EDUCATION, AND PATIENT UNDERSTANDING OF TREATMENTS.

Cleveland Clinic Abu Dhabi pioneers Focal One HIFU for prostate cancer

UAE — Cleveland Clinic Abu Dhabi, part of the M42 network, has added HighIntensity Focused Ultrasound (HIFU) to its prostate cancer treatment options.

HIFU is a minimally invasive procedure that uses focused ultrasound waves to precisely target and eliminate

cancerous tissue without incisions or anesthesia. Prior treatments included prostatectomy and radiation therapy.

Focal One HIFU therapy, performed under real-time robotic supervision, selectively targets cancer cells while minimizing damage to surrounding tissue.

Dr. Waleed Hassen, Department Chair of Urology, emphasizes its benefits for patients with low-volume cancer seeking to avoid more invasive treatments.

The implementation of Focal One HIFU therapy aligns with Cleveland Clinic Abu Dhabi’s commitment to providing world-class medical services and contributes to Abu Dhabi’s reputation as a center for medical excellence.

With prostate cancer being highly treatable, innovations like Focal One HIFU therapy improve the likelihood of successful outcomes for patients.

Philips unveils CT 5300 System with advanced AI capabilities

EUROPE — Royal Philips, a prominent figure in health technology, has unveiled its latest innovation, the Philips CT 5300 system, featuring advanced AI capabilities.

This cutting-edge X-ray CT system aims to revolutionize diagnosis, interventional procedures, and screening processes, elevating diagnostic confidence, streamlining workflow efficiency, and maximizing system uptime.

Unveiled at the European Congress of Radiology 2024, the CT 5300 addresses challenges in implementing a “CT first” strategy for triaging patients with undiagnosed coronary artery disease.

By integrating virtual tools for realtime collaboration and clinical support, it manages increased patient caseloads and complex cases effectively.

Engineered for sustainability, the CT 5300 lowers energy consumption while democratizing advanced medical technology. Operational in several European hospitals, it has received positive feedback for its comprehensive imaging capabilities.

The system’s standout feature is its Nanopanel Precise detector, coupled with Philips Precise Image reconstruction software, delivering high-quality images at lower radiation doses. With up to 80% lower dose and improved image quality, the CT 5300 excels in motion-free cardiac imaging.

Dolbey introduces new AI Technology to drive healthcare workflow automation

USA — Dolbey, a leading developer of healthcare solutions, has introduced AI Assist, a groundbreaking addition to its Fusion Narrate platform.

Powered by nVoq, AI Assist leverages generative AI to revolutionize healthcare workflow automation, marking a step forward in both speech recognition and automation technology.

AI Assist empowers healthcare providers with secure and HIPAAcompliant access to cutting-edge AI, streamlining their workflows by automating previously time-consuming tasks.

It offers text analysis, summarization, and generation capabilities, allowing providers to automatically generate

suggested impressions and recommendations, create concise reports with bulleted or numbered lists and improve the completeness of medical documentation.

Additionally, the product will help to suggest relevant ICD-10 billing codes as well as to build custom AI-driven workflows using the Fusion Narrate shortcut builder.

Curtis Weeks, Dolbey’s VP of Product Development, emphasizes the company’s commitment to innovation in healthcare.

“The positive response from early adopters underscores our commitment to innovation and excellence in the healthcare sector,” he added.

UK approves Rubidium Generator (RUBY-FILL) for heart imaging to diagnose coronary artery disease

UK - The Rubidium (Rb82) Generator (RUBY-FILL) has been approved by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for cardiac imaging, aiding in the diagnosis of coronary artery disease (CHD).

RUBY-FILL is a closed system that produces rubidium Rb 82 chloride injections for PET imaging of the myocardium.

It requires one or two injections administered by a doctor at least 10 minutes apart, with scans performed within 5 minutes.

This radiopharmaceutical collects temporarily in certain body parts, allowing detection with special cameras to assess blood flow to the heart. Despite containing a small amount of radioactivity, it poses a very low risk of cancer and hereditary abnormalities.

CHD, a leading cause of death globally, affects 2.3 million people in the UK annually. MHRA’s Julian Beach emphasized patient safety and access

to quality medical items, stating that regulatory standards for approval have been met.

MHRA will monitor RUBY-FILL’s safety and efficacy closely and encourages reporting any adverse effects through the Yellow Card initiative.

• Electrical medical equipment

• Patient monitoring equipment

• Surgical equipment

• Storage, transport and logistics solutions

• Patient mobility and support solutions

• Acute care and procedural equipment

• Consumables for use in medical facilities

• Automation and Merchandising solutions

• Cleaning, sanitisation and contamination control products and services

BUSINESS SUMMIT AFRICA

The Africa CEO Leadership & Sustainability Forum

www.africabizsummit.com

Events

SEPTEMBER 10-12, 2024 | Safari Park Hotel, Nairobi, Kenya

THE AFRICA CEO LEADERSHIP & SUSTAINABILITY FORUM

The Africa Business Summit is the ground-breaking executive level conference and expo on the future of strategic leadership, entrepreneurship, sustainability & african transformation

The program at the 3-day Summit comprises of a number of premium sessions such as Leadership Dialogues, CEO Roundtables, Plenary and Panel Discussions and a B2B Deal Connect Service as well as presentations by influential people and change makers who are making waves – and inspiring the next generation of leaders in Africa

Co-located with:

KEY AGENDA